[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 453
1. Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A: BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer; 2007 May 21;96(10):1549-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.
  • Frequency of a BRAF V600E mutation in anaplastic thyroid carcinoma, which is thought to be derived mainly from papillary carcinoma by multi-step carcinogenesis, is much lower than that in papillary carcinomas.
  • To clarify this phenomenon, we analysed BRAF V600E mutation in 20 cases of anaplastic carcinoma and 13 accompanying differentiated carcinomas.
  • Among twenty cases of anaplastic carcinomas, nine and four accompanied papillary and follicular carcinomas, respectively.
  • BRAF V600E mutation was found in three of nine (33.3%), none of four and one of seven (14.3%) anaplastic carcinomas with papillary carcinoma, follicular carcinoma and without differentiated components, respectively.
  • All three papillary carcinomas accompanied by anaplastic carcinoma with a BRAF V600E mutation were also shown to have a BRAF V600E mutation.
  • In summary, BRAF V600E mutation was occasionally observed in anaplastic carcinomas with papillary carcinoma, and the low frequency of BRAF V600E mutation in anaplastic carcinoma was thought to be due to the low frequency of anaplastic carcinomas with papillary carcinoma.
  • These findings raise a question about the classical model of anaplastic transformation and suggest some roles of thyroid cancer stem cells in the generation of anaplastic carcinoma.
  • [MeSH-major] Carcinoma / genetics. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. L-Valine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Semin Cancer Biol. 2007 Jun;17(3):233-40 [16569505.001]
  • [Cites] Pathology. 2002 Feb;34(1):94-7 [11902457.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4393-7 [12970315.001]
  • [Cites] Oncogene. 2003 Sep 25;22(41):6455-7 [14508525.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1365-8 [15001635.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):572-6 [15095090.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1359-63 [15195111.001]
  • [Cites] Endocrinol Metab Clin North Am. 1990 Sep;19(3):545-76 [2261906.001]
  • [Cites] Endocr Rev. 1994 Apr;15(2):202-32 [8026388.001]
  • [Cites] World J Surg. 1996 Sep;20(7):848-53; discussion 853 [8678961.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):287-94 [9516913.001]
  • [Cites] Endocr J. 2004 Dec;51(6):509-15 [15644567.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2261-8 [15880523.001]
  • [Cites] Thyroid. 2005 May;15(5):432-8 [15929664.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):245-62 [15947100.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9 [16174717.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • (PMID = 17453004.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 3KX376GY7L / Glutamic Acid; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; HG18B9YRS7 / Valine
  • [Other-IDs] NLM/ PMC2359941
  •  go-up   go-down


2. Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R: Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol; 2008 Feb;21(2):192-200
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of this study is to evaluate the expressions of these markers in thyroid tumors of the full spectrum of differentiation, with special emphasis on anaplastic carcinomas.
  • A total of 94 cases of thyroid neoplasms were studied: 17 papillary carcinomas, 18 follicular adenomas, 16 follicular carcinomas, 7 poorly differentiated carcinomas, 28 anaplastic carcinomas, and 8 medullary carcinomas.
  • The antibodies to Pax8 and TTF-2 were also applied on 147 lung carcinomas as well as a variety of normal tissues and malignant tumors.
  • All three markers were seen in papillary carcinomas, follicular adenomas and carcinomas, and poorly differentiated carcinomas in a diffuse manner, whereas their expressions in medullary carcinomas were variable.
  • Pax8 was expressed in 79% of anaplastic carcinomas to a variable extent, whereas TTF-1 and TTF-2 were seen only in 18 and 7% of anaplastic carcinomas, respectively.
  • Pax8 was expressed in renal tubules, fallopian tubes, ovarian inclusion cysts, and lymphoid follicles as well as renal carcinoma, nephroblastoma, seminoma, and ovarian carcinoma, but not in normal tissue and carcinomas of the lung.
  • Pax8 is a useful marker for the diagnosis of anaplastic carcinomas, particularly when the differential diagnosis includes pulmonary carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Adenosine Triphosphatases / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / metabolism. DNA-Binding Proteins / metabolism. Paired Box Transcription Factors / metabolism. Thyroid Neoplasms / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Calcitonin / metabolism. Carcinoma / diagnosis. Carcinoma / metabolism. Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / metabolism. Female. Fluorescent Antibody Technique, Indirect. Humans. Hyperplasia. Immunoenzyme Techniques. Male. Middle Aged. Thyroid Gland / metabolism. Thyroid Gland / pathology. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084247.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / Transcription Factors; 9007-12-9 / Calcitonin; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / TTF2 protein, human
  •  go-up   go-down


3. Ganguly R, Mitra S, Datta AK: Synchronous occurrence of anaplastic, follicular and papillary carcinomas with follicular adenoma in thyroid gland. Indian J Pathol Microbiol; 2010 Apr-Jun;53(2):337-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of anaplastic, follicular and papillary carcinomas with follicular adenoma in thyroid gland.
  • Various combinations of thyroid carcinomas have been reported including those between different cancers of follicular cell origin and those between follicular and C-cell histogenesis.
  • Accordingly, anaplastic carcinomas have been seen to coincide with simultaneous papillary and follicular cancers.
  • We report a case of composite anaplastic and papillary cancer on one thyroid lobe with a follicular carcinoma in the other lobe in a female patient aged 64 years.
  • The patient also had a separate and independent follicular adenoma in the same lobe as the composite anaplastic and papillary carcinoma.
  • The papillary carcinoma was continuous with the anaplastic carcinoma.
  • This could result from the dedifferentiation of a pre-existing differentiated carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / complications. Adenoma / complications. Carcinoma / complications. Carcinoma, Papillary / complications. Thyroid Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Pathol Microbiol. 2011 Apr-Jun;54(2):434-5 [21623130.001]
  • [CommentIn] Indian J Pathol Microbiol. 2011 Apr-Jun;54(2):414-5; author reply 415 [21623114.001]
  • (PMID = 20551551.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


Advertisement
4. Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, Viglietto G, Caleo A, Migliaccio I, Decaussin-Petrucci M, Santoro M, Palombini L, Fusco A: UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer; 2005 Aug 22;93(4):464-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas.
  • The hybridisation of an Affymetrix HG_U95Av2 oligonucleotide array with RNAs extracted from six human thyroid carcinoma cell lines and a normal human thyroid primary cell culture led us to the identification of the UbcH10 gene that was upregulated by 150-fold in all of the carcinoma cell lines in comparison to the primary culture cells of human normal thyroid origin.
  • Immunohistochemical studies performed on paraffin-embedded tissue sections showed abundant UbcH10 levels in thyroid anaplastic carcinoma samples, whereas no detectable UbcH10 expression was observed in normal thyroid tissues, in adenomas and goiters.
  • Papillary and follicular carcinomas were only weakly positive.
  • The block of UbcH10 protein synthesis induced by RNA interference significantly reduced the growth rate of thyroid carcinoma cell lines.
  • Taken together, these results would indicate that UbcH10 overexpression is involved in thyroid cell proliferation, and may represent a marker of thyroid anaplastic carcinomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / genetics. Carcinoma / pathology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology. Ubiquitin-Conjugating Enzymes / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;57(3):167-74 [2570483.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):908-11 [2914297.001]
  • [Cites] Cell. 1990 Feb 23;60(4):557-63 [2406025.001]
  • [Cites] Oncogene. 1990 Apr;5(4):565-70 [2183158.001]
  • [Cites] Endocrinology. 1991 Sep;129(3):1391-401 [1714832.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1369-71 [1737400.001]
  • [Cites] Oncogene. 1992 Dec;7(12):2549-53 [1334253.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jan;76(1):127-33 [8421076.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):179-84 [8423216.001]
  • [Cites] J Clin Invest. 1993 Apr;91(4):1753-60 [8473515.001]
  • [Cites] Am J Surg Pathol. 1993 Apr;17(4):375-81 [7684202.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2206-12 [8156527.001]
  • [Cites] J Clin Pathol. 1994 Apr;47(4):337-9 [8027371.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9004-8 [8090760.001]
  • [Cites] J Endocrinol Invest. 1995 Feb;18(2):130-3 [7629380.001]
  • [Cites] Horm Res. 1997;47(4-6):145-57 [9167946.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jun;82(6):1857-62 [9177396.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4094-100 [9398720.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):287-94 [9516913.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] Oncogene. 1998 Oct 22;17(16):2039-45 [9798675.001]
  • [Cites] Clin Cancer Res. 1996 Jan;2(1):119-26 [9816098.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5523-8 [9850089.001]
  • [Cites] Virology. 1964 Jun;23:291-4 [14187925.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Cell. 2000 Sep 1;102(5):549-52 [11007473.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5729-35 [11126359.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):608-14 [11807785.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4167-73 [12874022.001]
  • [Cites] J Clin Pathol. 2003 Aug;56(8):587-91 [12890807.001]
  • [Cites] Oncogene. 2003 Sep 25;22(41):6455-7 [14508525.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6621-9 [15208666.001]
  • [Cites] Mol Cell Biol. 1987 Sep;7(9):3365-70 [3670314.001]
  • [Cites] Virology. 1987 Nov;161(1):62-72 [2823470.001]
  • [Cites] Endocrinology. 1989 Oct;125(4):1783-8 [2551628.001]
  • (PMID = 16106252.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 6.3.2.19 / UBE2C protein, human; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes
  • [Other-IDs] NLM/ PMC2361574
  •  go-up   go-down


5. Kim HS, Kim GY, Lim SJ, Kim YW: Raf-1 kinase inhibitory protein expression in thyroid carcinomas. Endocr Pathol; 2010 Dec;21(4):253-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Raf-1 kinase inhibitory protein expression in thyroid carcinomas.
  • RKIP is reduced in a variety of human carcinomas, but RKIP expression in thyroid carcinomas has not been analyzed at the protein level.
  • In this study, we examined the immunohistochemical expression of RKIP in various subtypes of thyroid carcinoma.
  • Immunostaining for RKIP was performed on 104 cases of primary thyroid carcinoma (40 papillary, 29 follicular, 11 medullary, 11 poorly differentiated, and 13 anaplastic carcinomas) and 26 cases of nodal metastatic tumor (17 papillary, 4 medullary, and 5 anaplastic carcinomas).
  • Normal thyroid tissue and all cases of follicular, papillary, and medullary carcinomas showed uniform, strong cytoplasmic immunoreactivity for RKIP.
  • With the exception of one case, poorly differentiated carcinomas also revealed strong RKIP expression.
  • In contrast, RKIP expression was completely absent in all anaplastic carcinomas.
  • The transition zone from the differentiated carcinoma component (strong RKIP expression) to the anaplastic carcinoma component (no RKIP expression) demonstrated a completely opposite pattern of RKIP immunoreactivity.
  • This reduction of RKIP expression in anaplastic carcinoma was statistically significant (P < 0.0001).
  • Additionally, RKIP expression of nodal metastatic tumors corresponded with that of primary tumors: metastatic papillary and medullary carcinomas showed uniform, strong cytoplasmic RKIP immunoreactivity, in contrast, in metastatic anaplastic carcinomas, RKIP expression was completely absent.
  • RKIP expression is significantly reduced in anaplastic thyroid carcinoma as compared to other subtypes of thyroid carcinoma.
  • Further studies are necessary to elucidate the precise mechanism of RKIP action in anaplastic thyroid carcinoma.
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adolescent. Adult. Aged. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):24931-40 [15886202.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):321-30 [1695118.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4437-42 [17201166.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(21):7207-17 [11585904.001]
  • [Cites] Minerva Endocrinol. 2008 Dec;33(4):341-57 [18923370.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):453-64 [16474910.001]
  • [Cites] J Biol Chem. 2001 Oct 26;276(43):39772-8 [11514577.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):524-9 [18375747.001]
  • [Cites] Mol Cancer Res. 2009 Jun;7(6):832-40 [19531568.001]
  • [Cites] J Biol Chem. 2004 Dec 24;279(52):54610-9 [15475567.001]
  • [Cites] J Proteome Res. 2008 Dec;7(12):5254-62 [19367706.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7392-7 [16243812.001]
  • [Cites] Hum Pathol. 2010 Nov;41(11):1609-16 [20688353.001]
  • [Cites] J Mol Biol. 2001 Jul 13;310(3):617-34 [11439028.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5672-9 [17179102.001]
  • [Cites] FEBS Lett. 1995 Jan 9;357(3):290-6 [7835430.001]
  • [Cites] Prostate. 2006 Feb 15;66(3):248-56 [16175585.001]
  • [Cites] Med Oncol. 2010 Jun;27(2):219-23 [19291429.001]
  • [Cites] Nature. 2003 Dec 4;426(6966):574-9 [14654844.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):1068-81 [15761501.001]
  • [Cites] Nature. 1999 Sep 9;401(6749):173-7 [10490027.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):2994-3001 [18483365.001]
  • [Cites] J Mol Endocrinol. 2009 Oct;43(4):143-55 [19383830.001]
  • [Cites] Biochem J. 1994 Jul 1;301 ( Pt 1):235-42 [8037677.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):820-7 [17439843.001]
  • (PMID = 20734161.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PEBP1 protein, human; 0 / Phosphatidylethanolamine Binding Protein
  •  go-up   go-down


6. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, Liu CG, Petrocca F, Troncone G, Calin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, Fusco A: Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene; 2007 Nov 29;26(54):7590-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific microRNAs are downregulated in human thyroid anaplastic carcinomas.
  • Thyroid carcinomas comprise a broad spectrum of tumors with different clinical behaviors.
  • On the one side, there are occult papillary carcinomas (PTC), slow growing and clinically silent, and on the other side, rapidly growing anaplastic carcinomas (ATC), which are among the most lethal human neoplasms.
  • [MeSH-major] Carcinoma / genetics. Chromosome Mapping. Gene Expression Regulation. MicroRNAs / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17563749.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MIRN510 microRNA, human; 0 / MicroRNAs; 0 / RNA, Neoplasm
  •  go-up   go-down


7. Motti ML, Califano D, Baldassarre G, Celetti A, Merolla F, Forzati F, Napolitano M, Tavernise B, Fusco A, Viglietto G: Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis; 2005 Jun;26(6):1021-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas.
  • We found that cells derived from differentiated carcinoma (TPC-1, WRO) arrest in G(1) phase at confluence, whereas cells derived from anaplastic carcinoma (ARO, FRO and FB1) continue to grow after reaching confluence.
  • In summary, our data indicate that the altered response to contact inhibition exhibited by thyroid anaplastic cancer cells is due to the failure to upregulate p27(Kip1) in response to cell-cell interactions.
  • [MeSH-major] Cadherins / biosynthesis. Carcinoma / metabolism. Cell Cycle Proteins / physiology. Contact Inhibition / physiology. Thyroid Neoplasms / metabolism. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Communication. Cell Count. Cell Line, Tumor. Cell Proliferation. Cyclin A / metabolism. Cyclin-Dependent Kinase Inhibitor p27. Cyclin-Dependent Kinases / metabolism. Cyclins / metabolism. Cytoskeletal Proteins / biosynthesis. Gene Expression Regulation, Neoplastic. Humans. Trans-Activators / biosynthesis. beta Catenin

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15718252.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cell Cycle Proteins; 0 / Cyclin A; 0 / Cyclins; 0 / Cytoskeletal Proteins; 0 / Trans-Activators; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


8. Ito Y, Arai K, Nozawa R, Yoshida H, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Kuma K, Miyauchi A: S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma. Anticancer Res; 2007 Jul-Aug;27(4C):2679-83
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S100A10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma.
  • BACKGROUND: S100A10, a member of the S100 family, forms a heterotetramer with annexin IIH and promotes carcinoma invasion and metastasis by plasminogen activation.
  • Cells stained positively in 14.6% and 20.8% of follicular carcinomas for S100A10 and annexin II, respectively, but their expression levels were always low.
  • S100A10 and annexin II were expressed in all papillary carcinomas, but 88.2% and 82.8% ofpapillary carcinomas were classified in the low group.
  • S100S10 and annexin II were also expressed in all anaplastic carcinomas, with 83.3% of these lesions were classified in the high group.
  • CONCLUSION: These findings suggest that S100A10 and annexin II contribute to the aggressive characteristics of anaplastic carcinoma, while playing a constitutive role in papillary carcinoma.
  • [MeSH-major] Annexin A2 / biosynthesis. Carcinoma / metabolism. Carcinoma / pathology. S100 Proteins / biosynthesis. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Epithelium / metabolism. Epithelium / pathology. Humans. Immunohistochemistry. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695432.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Annexin A2; 0 / S100 Proteins; 0 / S100 calcium binding protein A10
  •  go-up   go-down


9. Colonna M, Bossard N, Guizard AV, Remontet L, Grosclaude P, le réseau FRANCIM: Descriptive epidemiology of thyroid cancer in France: incidence, mortality and survival. Ann Endocrinol (Paris); 2010 Mar;71(2):95-101
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overall and relative survivals by sex and age (diagnosis period 1989-1997; cut-off date 1st January 2002) were obtained from the dedicated and nine other registries.
  • The main increasing subtype was papillary carcinoma.
  • The highest survival (>94%) concerned papillary carcinomas and the lowest (<15%) anaplastic carcinomas.
  • Survivals were generally higher in women than in men; precisely, higher in women for papillary and follicular carcinomas but higher in men for medullary and anaplastic carcinomas.
  • Survivals increased with age, but for medullary carcinomas.
  • Survivals from anaplastic carcinomas were very low whatever the age.
  • [MeSH-major] Adenocarcinoma, Follicular / epidemiology. Carcinoma / epidemiology. Carcinoma, Medullary / epidemiology. Carcinoma, Papillary / epidemiology. Thyroid Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20036351.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Investigator] Velten M; Launoy G; Troussard X; Guizard AV; Faivre J; Colonna M; Arveux P; Maynadié M; Danzon A; Gouerou H; Buemi A; Tretarre B; Bara S; Ganry; Grosclaude P; Kadi-Hanifi AM; Molinié F; Monnereau A; Schvartz C; Baldi I; Saves M; Guerrin-Tran E; Ligier K; Dieye M; Plenet J
  •  go-up   go-down


10. Mansouri H, Gaye M, Errihani H, Kettani F, Gueddari BE: Leiomyosarcoma of the thyroid gland. Acta Otolaryngol; 2008 Mar;128(3):335-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some authors believe that thyroid sarcomas are, in fact, anaplastic carcinomas with sarcomatous (spindle cell) features.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease Progression. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Middle Aged. Mitotic Index. Neoplasm Invasiveness. Thyroid Gland / pathology. Thyroidectomy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18274920.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Pauser U, Kosmahl M, Sipos B, Klöppel G: [Mesenchymal tumors of the pancreas. Surprising, but not uncommon]. Pathologe; 2005 Feb;26(1):52-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is important to differentiate these tumors from anaplastic carcinomas and retroperitoneal tumors that infiltrate pancreatic tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol Hepatol. 2004 Apr;19(4):467-70 [15012791.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(5):419-22 [8322457.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):613-7 [12808068.001]
  • [Cites] Am J Surg Pathol. 1981 Sep;5(6):597-602 [7325276.001]
  • [Cites] Virchows Arch. 2002 Feb;440(2):128-33 [11964041.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2150-8 [9610694.001]
  • [Cites] Acta Pathol Jpn. 1985 Jul;35(4):975-9 [4072679.001]
  • [Cites] Br Med J. 1977 Mar 26;1(6064):814 [851741.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1720-3 [7370927.001]
  • [Cites] Pancreas. 2003 Jul;27(1):14-9 [12826900.001]
  • [Cites] Histopathology. 2001 Feb;38(2):105-10 [11207823.001]
  • [Cites] Histopathology. 1998 Nov;33(5):485-7 [9839177.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):37-42 [10431844.001]
  • [Cites] Hum Pathol. 1992 Nov;23(11):1309-12 [1427759.001]
  • [Cites] Ann Diagn Pathol. 2001 Jun;5(3):129-40 [11436166.001]
  • [Cites] Histopathology. 1993 Nov;23(5):475-7 [8314223.001]
  • [Cites] J Thorac Cardiovasc Surg. 1970 Sep;60(3):392-401 [5451736.001]
  • [Cites] Pediatr Radiol. 1983;13(5):287-9 [6622090.001]
  • [Cites] Mod Pathol. 1994 Feb;7(2):200-4 [7911997.001]
  • [Cites] J Radiol. 2001 Dec;82(12 Pt 1):1723-5 [11917638.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1040-7 [12170091.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2303-8 [2553244.001]
  • [Cites] Ultrastruct Pathol. 1998 May-Jun;22(3):227-31 [9793202.001]
  • [Cites] Arch Pathol Lab Med. 2003 Nov;127(11):1513-6 [14567749.001]
  • [Cites] Pathologe. 1997 May;18(3):233-7 [9273541.001]
  • [Cites] Hum Pathol. 1989 Dec;20(12):1215-7 [2556342.001]
  • [Cites] J Pediatr Surg. 1976 Oct;11(5):827-30 [993954.001]
  • [Cites] Acta Pathol Jpn. 1987 Mar;37(3):503-10 [3618222.001]
  • [Cites] Mod Pathol. 1998 Dec;11(12):1178-82 [9872648.001]
  • [Cites] Pathologe. 2002 Mar;23 (2):161-6 [12001534.001]
  • [Cites] Am J Surg Pathol. 1998 Apr;22(4):412-8 [9537467.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):198-200 [11319298.001]
  • [Cites] Am J Gastroenterol. 1994 Aug;89(8):1261-2 [8053450.001]
  • (PMID = 15592845.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Simeonov R, Simeonova G: Fractal dimension of canine mammary gland epithelial tumors on cytologic smears. Vet Clin Pathol; 2006 Dec;35(4):446-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The fractal dimension of nuclear surface was determined by computer-assisted morphometry on Hemacolor-stained cytologic smears obtained by fine needle aspiration of normal canine mammary gland epithelial cells, and cells in mammary adenomas, tubulopapillary carcinomas, solid carcinomas, and anaplastic carcinomas.
  • RESULTS: Significant differences (P <.001) were observed in mean fractal dimension among all tumor types and in comparison with normal canine mammary gland epithelial cells (except for the fractal dimension between solid carcinomas and anaplastic carcinomas).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123252.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Ziadi S, Trimeche M, Zermani R, Elmay A, Baltagi-Ben Jilani S: [Diagnostic contribution of HBME-1 and anti-cytokeratin-19 antibodies in thyroid pathology: a retrospective study of 163 cases]. Tunis Med; 2005 May;83(5):274-8
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 92% (46/50 cases) of papillary carcinomas expressed HBME-1 as well as 50% (8/16 cases) of follicular carcinomas and 15% (6/40 cases) of follicular adenomas.
  • 8 insular carcinomas, 5 anaplastic carcinomas, 20 cases of Basedow disease and lymphocytic thyroiditis, and the 24 cases of nodular goiters did not express it or very focally.
  • Anti-cytokératine-19 marked 92% of papillary carcinomas, 56.2% of follicular carcinomas, 100% of the medullar carcinomas and 45% of follicular adenomas.
  • Whereas the cases of anaplastic carcinomas, Basedow disease, thyroiditis and the cases of nodular goiters were negative or focally marked.
  • CONCLUSION: HBME-1 is an excellent marker for papillary carcinoma which can be helpful in the diagnosis of its follicular variant; the association with anti-cytokératine-19 increases its specificity.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Keratins / analysis. Keratins / immunology. Thyroid Diseases / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Antibodies. Biomarkers / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044900.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / HBME-1 antigen; 68238-35-7 / Keratins
  •  go-up   go-down


14. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P: Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • V600E BRAF is the most common kinase mutation in melanoma (60%), also found in colorectal carcinomas (10%), most anaplastic and papillary thyroid carcinomas, and low-grade serous ovarian carcinomas.
  • RESULTS: 54 pts have been enrolled: metastatic melanoma (n=49), thyroid (n=3), rectal (n=1), or ovarian carcinoma (n=1).
  • 5 of the 7 BRAF V600E+ pts treated at ≥ 240 mg BID had tumor regression, up to 83%, with 1 confirmed partial response (PR) and 1 unconfirmed PR (too early); 2 of 4 pts with unknown V600E status had tumor regression, up to 50%, with 1 confirmed PR; 2 BRAF wild-type pts had progressive disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962338.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Nagaiah G, Fu P, Wasman JK, Cooney MM, Mooney C, Afshin D, Lavertu P, Bokar J, Savvides P, Remick SC, CTRU Research Nurses: Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC). J Clin Oncol; 2009 May 20;27(15_suppl):6058

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC).
  • This trial is ongoing and supported in part by NIH grant nos. CA62502.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Jakab C, Rusvai M, Gálfi P, Mándoki M, Demeter Z, Szabó Z, Kulka J: Expression of claudin-5 in hepatoid gland biopsies. Vet Dermatol; 2010 Jun;21(3):276-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These included normal hepatoid glands (n = 10), nodular hyperplasia (n = 10), adenomas (n = 12), epitheliomas (n = 15), differentiated carcinomas (n = 15) and anaplastic carcinomas (n = 15).
  • Claudin-5 expression seemed to be helpful in distinguishing poorly differentiated carcinomas, differentiated carcinomas and epitheliomas of the hepatoid glands.
  • Increased claudin-5 expression by invasive anaplastic carcinomas may facilitate invasion and metastasis through the activation of matrix metalloproteinases.
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adenoma / veterinary. Animals. Biopsy. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma / veterinary. Dogs. Endothelium / pathology. Female. Hyperplasia / veterinary. Male. Skin / pathology. Tight Junctions / metabolism. Tight Junctions / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20136787.001).
  • [ISSN] 1365-3164
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Claudins
  •  go-up   go-down


17. Lee JW, Yoon DY, Choi CS, Chang SK, Yun EJ, Seo YL, Rho YS, Cho SJ, Kim KH: Anaplastic thyroid carcinoma: computed tomographic differentiation from other thyroid masses. Acta Radiol; 2008 Apr;49(3):321-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma: computed tomographic differentiation from other thyroid masses.
  • BACKGROUND: Anaplastic thyroid carcinoma is rare but is one of the most aggressive malignancies.
  • Therefore, accurate diagnosis is important in order to provide appropriate therapy.
  • PURPOSE: To establish useful computed tomographic (CT) criteria for differentiating anaplastic carcinoma from other thyroid masses.
  • MATERIAL AND METHODS: The CT scans of nine patients with anaplastic carcinomas were retrospectively reviewed and compared with those of 32 patients with papillary carcinomas (n = 12) or benign lesions (n = 20) exceeding a maximum diameter of 2.0 cm.
  • RESULTS: Anaplastic carcinomas appeared as large (average 4.6 cm), solid (100%), and ill-defined (88.9%) masses accompanied by necrosis (100%), nodular calcification (44.4%), direct invasion into the adjacent organs (55.6%), and cervical lymph node involvement (77.8%).
  • Tumor necrosis was the most valuable parameter in differentiating anaplastic carcinomas from other thyroid masses.
  • Patient age (>70 years) and low attenuation value on postcontrast scan (attenuation value <100 HU, or M/m attenuation ratio <1.3) are also helpful predictors for anaplastic carcinoma.
  • CONCLUSION: If a patient is older than 70 years of age and has a large necrotic thyroid mass of low attenuation, anaplastic carcinoma should be included in the differential diagnosis.
  • [MeSH-major] Carcinoma / diagnosis. Thyroid Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anaplasia / pathology. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted / methods. Iohexol. Male. Middle Aged. Radiographic Image Enhancement / methods. Rare Diseases. Reproducibility of Results. Retrospective Studies. Thyroid Gland / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365821.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


18. Sobrinho-Simões M, Máximo V, Rocha AS, Trovisco V, Castro P, Preto A, Lima J, Soares P: Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am; 2008 Jun;37(2):333-62, viii
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As such, this article addresses the following aspects of intragenic mutations in thyroid cancer: thyroid stimulating hormone receptor and guanine-nucleotide-binding proteins of the stimulatory family mutations in hyperfunctioning tumors; mutations in RAS and other genes and aneuploidy; PAX8-PPARgamma rearrangements; BRAF mutations; mutations in oxidative phosphorylation and Krebs cycle genes in Hürthle cell tumors; mutations in succinate dehydrogenase genes in medullary carcinoma and C-cell hyperplasia; and mutations in TP53 and other genes in poorly differentiated and anaplastic carcinomas.
  • [MeSH-major] Carcinoma / genetics. Mutation. Thyroid Neoplasms / genetics

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502330.001).
  • [ISSN] 0889-8529
  • [Journal-full-title] Endocrinology and metabolism clinics of North America
  • [ISO-abbreviation] Endocrinol. Metab. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; 0 / Receptors, Thyrotropin; 0 / Recombinant Fusion Proteins; EC 1.3.99.1 / Succinate Dehydrogenase; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.1.- / GTP-Binding Proteins
  • [Number-of-references] 229
  •  go-up   go-down


19. Yamada H, Takano T, Ito Y, Matsuzuka F, Miya A, Kobayashi K, Yoshida H, Watanabe M, Iwatani Y, Miyauchi A: Expression of nestin mRNA is a differentiation marker in thyroid tumors. Cancer Lett; 2009 Jul 18;280(1):61-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unexpectedly, nestin mRNA was detected in almost all differentiated thyroid tumors and normal thyroid tissues, whereas extremely decreased expression was observed in anaplastic carcinomas, which are the most malignant of the thyroid follicular cell-derived tumors.
  • [MeSH-major] Carcinoma / metabolism. Gene Expression Regulation, Neoplastic. Intermediate Filament Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis. RNA, Messenger / metabolism. Thyroid Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19268442.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


20. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL, El-Naggar AK: Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol; 2008 Jan;39(1):15-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification.
  • Anaplastic thyroid carcinoma is a rare and universally fatal disease.
  • To determine the role of growth factor receptors in the biologic stratification of anaplastic thyroid carcinoma, we studied the expression of epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor beta, and HER-2 receptor in a large cohort of anaplastic thyroid carcinomas by immunohistochemical techniques.
  • The percentage of positive cells, staining intensity and localization of staining in the anaplastic component, and coexisting well-differentiated thyroid carcinoma and adjacent nonneoplastic thyroid were evaluated for these markers.
  • EGFR, platelet-derived growth factor receptor beta, and HER-2 were overexpressed in 58%, 16%, and 16% of anaplastic carcinomas, respectively.
  • In tumors with adjacent normal thyroid parenchyma and/or differentiated carcinoma components, overexpression of all 3 markers was noted exclusively in the anaplastic component.
  • Mutational analysis of exons 18, 19, and 21 of the EGFR gene showed no mutations in all anaplastic carcinomas.
  • We conclude that the expression of these markers (1) may play a role in a subset of thyroid tumorigenesis and anaplastic transformation and (2) can be validated for potential use in the stratification of patients for targeted therapy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Receptors, Growth Factor / metabolism. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17949783.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Growth Factor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


21. Simeonov R, Simeonova G: Computerized cytomorphometric analysis of nuclear area, nuclear perimeter and mean nuclear diameter in spontaneous canine mammary gland tumours. Vet Res Commun; 2007 Jul;31(5):553-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty-two spontaneous canine mammary gland tumours (fibroadenomas (n=8), tubulopapillary carcinomas (n=9), solid carcinomas (n=6), anaplastic carcinomas (n=7), fibrosarcomas (n=9), liposarcomas (n=9) and osteosarcomas (n=4) were analysed by computer-assisted nuclear morphometry in Hemacolor-stained cytological specimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comp Pathol. 1997 Aug;117(2):99-105 [9352434.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5A):3273-80 [11062753.001]
  • [Cites] J Clin Pathol. 1997 May;50(5):365-70 [9215116.001]
  • [Cites] J Comp Pathol. 1995 May;112(4):429-33 [7593765.001]
  • [Cites] J Comp Pathol. 2002 Aug-Oct;127(2-3):114-7 [12354521.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Jun;22(3):185-92 [10872033.001]
  • [Cites] Am J Vet Res. 1998 Oct;59(10):1238-42 [9781454.001]
  • [Cites] Am J Vet Res. 2002 Mar;63(3):363-9 [11926179.001]
  • [Cites] Am J Vet Res. 1995 Feb;56(2):185-7 [7717583.001]
  • [Cites] Vet Clin Pathol. 2002;31(1):16-8 [12019473.001]
  • [Cites] J Comp Pathol. 2004 Feb-Apr;130(2-3):143-51 [15003472.001]
  • [Cites] Vet Pathol. 2003 May;40(3):268-75 [12724567.001]
  • [Cites] Res Vet Sci. 1995 May;58(3):277-81 [7659856.001]
  • [Cites] Am J Vet Res. 2000 Sep;61(9):1074-9 [10976739.001]
  • [Cites] J Comp Pathol. 2001 Aug-Oct;125(2-3):117-21 [11578126.001]
  • [Cites] Am J Vet Res. 1992 Mar;53(3):300-3 [1595955.001]
  • (PMID = 17221362.001).
  • [ISSN] 0165-7380
  • [Journal-full-title] Veterinary research communications
  • [ISO-abbreviation] Vet. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


22. Krzeslak A, Gaj Z, Pomorski L, Lipinska A: Expression of cytokeratin 19 in the cytosolic fraction of thyroid lesions: ELISA and Western blot analysis. Mol Med Rep; 2008 Jul-Aug;1(4):565-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results of several studies suggest that CK19 may be useful in the diagnosis of papillary carcinoma, where it has been shown to have strong diffuse cytoplasmic reactivity.
  • However, the published results vary, and the utility of CK19 in the diagnosis of thyroid lesions is controversial.
  • The aim of this study was to evaluate, by Western blot analysis and the enzyme-linked immunosorbent assay (ELISA), the expression of CK19 in the cytosolic fraction obtained from 125 specimens of various thyroid lesions: nodular goiters, follicular adenomas, papillary carcinomas, follicular carcinomas and anaplastic carcinomas.
  • The analysis of CK19 expression using the ELISA showed that the majority of papillary carcinoma cases had a much higher level of CK19 than did nodular goiters and adenomas (P<0.001).
  • Western blot analysis revealed the presence of CK19 in 66% of papillary carcinoma cases.
  • CK19 expression was also found in 11, 22, 25 and 25% of nodular goiters, follicular adenomas, and follicular and anaplastic carcinomas, respectively.
  • The results demonstrate that the evaluation of CK19 expression may be helpful in distinguishing papillary carcinoma from other benign and malignant thyroid nodules, but cannot by itself be used to establish a diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21479451.001).
  • [ISSN] 1791-2997
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


23. Wreesmann VB, Singh B: Clinical impact of molecular analysis on thyroid cancer management. Surg Oncol Clin N Am; 2008 Jan;17(1):1-35, vii
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid cancer constitutes a progressive continuum of disease ranging from indolent well-differentiated carcinomas to aggressive poorly differentiated carcinomas and universally fatal anaplastic carcinomas.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18177798.001).
  • [ISSN] 1055-3207
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / beta Catenin
  • [Number-of-references] 245
  •  go-up   go-down


24. Babál P, Janega P, Cerná A, Kholová I, Brabencová E: Neoplastic transformation of the thyroid gland is accompanied by changes in cellular sialylation. Acta Histochem; 2006;108(2):133-40
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate associations between neoplastic changes in the thyroid gland and changes in sialylation, with reference to its terminal linkage type.
  • These included papillary, follicular, oncocytic, medullary and anaplastic carcinomas, follicular adenomas and benign follicular and parenchymatous goiter.
  • Strong luminal positivity for sialic acid was found in papillary carcinomas, whereas moderate positivity was seen in follicular carcinomas.
  • Inconsistent, weak positivity for sialic acid was documented in medullary and anaplastic carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720036.001).
  • [ISSN] 0065-1281
  • [Journal-full-title] Acta histochemica
  • [ISO-abbreviation] Acta Histochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


25. Xiao GQ, Unger PD, Burstein DE: Immunohistochemical detection of X-linked inhibitor of apoptosis (XIAP) in neoplastic and other thyroid disorders. Ann Diagn Pathol; 2007 Aug;11(4):235-40
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 35 papillary thyroid carcinomas (PTCs), 29 (83%) stained variably in intensity and/or extent.
  • An insular carcinoma was strongly positive and 1 of 4 anaplastic carcinomas moderately positive.
  • Follicular, medullary, and 3 of 4 anaplastic carcinomas, oncocytic neoplasms, and a hyalinizing trabecular tumor were nonstaining.
  • Because XIAP was highly specific for PTC among the thyroid neoplasms, it may be a useful marker for differential diagnosis when used alone or in combination with other markers.
  • XIAP may also be useful in differentiating insular carcinoma from follicular neoplasm in certain difficult cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630106.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / X-Linked Inhibitor of Apoptosis Protein
  •  go-up   go-down


26. Jung YH, Hah JH, Sung MW, Kim KH, Cho SY, Jeon YK: Reciprocal immunohistochemical expression of sodium/iodide symporter and hexokinase I in primary thyroid tumors with synchronous cervical metastasis. Laryngoscope; 2009 Mar;119(3):541-8
Hazardous Substances Data Bank. IODINE, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Nine cases of follicular carcinomas, sixteen cases of papillary carcinomas, and four cases of anaplastic carcinomas were included.
  • RESULTS: NIS had a positive expression in good prognostic types of thyroid carcinomas, such as follicular carcinomas, more often, while having a positive expression in poor prognostic types of thyroid carcinomas, such as anaplastic carcinomas (P = .033) less often; HK I had the opposite pattern of expression (P = .033).
  • [MeSH-major] Carcinoma / metabolism. Symporters / biosynthesis. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19235753.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Symporters; 0 / sodium-iodide symporter; 9679TC07X4 / Iodine
  •  go-up   go-down


27. Weinberger PM, Adam BL, Gourin CG, Moretz WH 3rd, Bollag RJ, Wang BY, Liu Z, Lee JR, Terris DJ: Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg; 2007 May;133(5):503-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma.
  • Among carcinomas, cytoplasmic galectin-3 expression was observed in papillary thyroid carcinomas (82%) and follicular (33%) and medullary (9%) carcinomas but was absent in anaplastic carcinomas (P<.001).
  • Galectin-3 nuclear expression was observed in papillary thyroid carcinomas (62%) and follicular carcinomas (33%) but was undetectable in medullary, anaplastic carcinomas (P<.001).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515507.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Galectin 3; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Wnt Proteins; 0 / beta Catenin; 0 / cytoplasmic activator protein, human
  •  go-up   go-down


28. Kim YW, Do IG, Park YK: Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas. Pathol Res Pract; 2006;202(11):759-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas.
  • Only few studies have evaluated the usefulness of the GLUT1 and p63 status of thyroid carcinomas in revealing tumorigenesis.
  • We studied GLUT1, p53, and p63 immunoexpression in a total of 86 cases of various thyroid carcinoma types to determine the biological significance of GLUT1 and p63 expression in thyroid carcinomas.
  • GLUT1 was detected in six cases of anaplastic carcinoma and in one case of poorly differentiated carcinoma with membranous staining. p63 was detected in five cases of anaplastic carcinoma, in one case of poorly differentiated carcinoma, and in five cases of papillary carcinoma with nuclear positivity. p53 was detected in six cases of anaplastic carcinoma, in one case of poorly differentiated carcinoma, and in one case of follicular carcinoma with nuclear positivity.
  • Five of seven cases of anaplastic carcinoma expressed all three of these markers.
  • The results suggest that GLUT1, p63, and p53 are not expressed in well-differentiated thyroid carcinomas, and that they are usually expressed late in the course of thyroid tumor progression.
  • These data strongly suggest that in anaplastic carcinomas, impairment of p53-mediated repression results in increased GLUT1 and p63 expression, and that this probably reflects the differential regulation of hypoxia-responsive pathways and basal/stem cell regulatory pathways.
  • [MeSH-major] Biomarkers, Tumor / analysis. Glucose Transporter Type 1 / biosynthesis. Membrane Proteins / biosynthesis. Thyroid Neoplasms / metabolism. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17029809.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Glucose Transporter Type 1; 0 / Membrane Proteins; 0 / SLC2A1 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


29. Ito Y, Yoshida H, Tomoda C, Uruno T, Miya A, Kobayashi K, Matsuzuka F, Kakudo K, Kuma K, Miyauchi A: Expression of S100A2 and S100A6 in thyroid carcinomas. Histopathology; 2005 May;46(5):569-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of S100A2 and S100A6 in thyroid carcinomas.
  • AIMS: S100 calcium-binding proteins are known to play multiple roles in carcinoma development.
  • Although 89.5% of papillary carcinoma were positive for S100A2, the expression was heterogeneous except in two cases.
  • In anaplastic carcinoma, 78.5% of cases expressed S100A2 diffusely, while the remaining cases were negative.
  • In normal follicles, S100A6 expression was always low, while 8.3% of follicular adenomas and 39.5% of follicular carcinomas showed increased expression.
  • In papillary carcinomas, S100A6 expression was increased in 75% of cases, but in anaplastic carcinomas it was decreased, with only 14.3% showing high expression.
  • CONCLUSIONS: The expression patterns of S100A2 and S100A6 in thyroid neoplasms are unique compared with those of other carcinomas, suggesting that: (i) S100A2 and S100A6 contribute to certain events in papillary carcinoma progression, and (ii) S100A2 expression is one of the biological characteristics of anaplastic carcinoma.
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842639.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Chemotactic Factors; 0 / S100 Proteins; 0 / S100A2 protein, human; 105504-00-5 / S100A6 protein, human
  •  go-up   go-down


30. Schmid KW: [Problem areas of tumour classifications--thyroid carcinomas]. Verh Dtsch Ges Pathol; 2007;91:57-65
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Problem areas of tumour classifications--thyroid carcinomas].
  • Thyroid carcinoma has been traditionally subdivided into the four major groups papillary, follicular, medullary, and anaplastic carcinoma.
  • The WHO classification of thyroid tumours, published in 2004, has added to these four tumour groups the entity of poorly differentiated carcinoma as well as a broad variety of rare thyroid malignancies.
  • Another important change concerns the histological hallmarks of papillary carcinoma, the diagnosis of which is now exclusively dependent on characteristic nuclear features.
  • The aim of the present paper is to highlight diagnostic problems particularly caused by the alteration introduced onto the WHO classification, This includes a proposal of a more systematic thyroid carcinoma classification based on the histogenetic differentiation (follicular cell differentiation.
  • C cell differentiation, rare carcinomas) and tumour grading of carcinomas with follicular cell differentiation (differentiated, poorly differentiated and anaplastic carcinomas) as well as commentaries on the diagnosis of papillary carcinoma, poorly differentiated carcinoma, and rare types of thyroid carcinoma (squamous cell carcinoma, mucoepidermoid carcinoma, sclerosing mucoepidermoid carcinoma with eosinophilia, mucinous carcinoma, SETTLE, and CASTLE).
  • [MeSH-major] Carcinoma / classification. Thyroid Neoplasms / classification
  • [MeSH-minor] Carcinoma, Papillary / classification. Carcinoma, Papillary / pathology. Humans. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18314596.001).
  • [ISSN] 0070-4113
  • [Journal-full-title] Verhandlungen der Deutschen Gesellschaft für Pathologie
  • [ISO-abbreviation] Verh Dtsch Ges Pathol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 37
  •  go-up   go-down


31. Ito Y, Takano T, Miyauchi A: Apolipoprotein e expression in anaplastic thyroid carcinoma. Oncology; 2006;71(5-6):388-93
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apolipoprotein e expression in anaplastic thyroid carcinoma.
  • However, recently the relationship between Apo E and carcinoma progression has been investigated.
  • In this study, we investigated Apo E expression in thyroid carcinoma at both the protein and molecular levels.
  • RESULTS: In RT-PCR and in situ hybridization, the Apo E mRNA expression level was very low in papillary and follicular carcinomas as well as normal thyroid, but was dramatically elevated in anaplastic carcinoma.
  • In an immunohistochemical study, 32 of 33 anaplastic carcinomas (97.0%) showed high levels of Apo E expression, but this phenomenon was seen only in 1 of 51 papillary carcinomas (2.0%).
  • None of the follicular carcinomas or adenomas showed high levels of Apo E expression.
  • CONCLUSIONS: These findings suggest that Apo E is one of the typical biological characteristics of anaplastic thyroid carcinoma.
  • [MeSH-major] Adenoma / metabolism. Apolipoproteins E / biosynthesis. Biomarkers, Tumor / biosynthesis. Carcinoma / metabolism. Carcinoma, Papillary / metabolism. Thyroid Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17690558.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


32. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, Bussolati G, Rosai J: Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol; 2007 Aug;31(8):1256-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach.
  • Poorly differentiated (PD) thyroid carcinomas lie both morphologically and behaviorally between well-differentiated and undifferentiated (anaplastic) carcinomas.
  • To compare lesions occurring in different geographic areas and the diagnostic criteria applied in those countries, we designed a study with a panel of internationally recognized thyroid pathologists to develop consensus diagnostic criteria for PD carcinomas.
  • A consensus meeting was then held in Turin, Italy, where an agreement was reached concerning the diagnostic criteria for PD carcinoma.
  • These include (1) presence of a solid/trabecular/insular pattern of growth, (2) absence of the conventional nuclear features of papillary carcinoma, and (3) presence of at least one of the following features: convoluted nuclei; mitotic activity >or=3 x 10 HPF; and tumor necrosis.
  • An algorithmic approach was devised for practical use in the diagnosis of this tumor.
  • [MeSH-major] Adenocarcinoma / diagnosis. Algorithms. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667551.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


33. Liptak JM, Kamstock DA, Dernell WS, Ehrhart EJ, Rizzo SA, Withrow SJ: Cranial mediastinal carcinomas in nine dogs. Vet Comp Oncol; 2008 Mar;6(1):19-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cranial mediastinal carcinomas in nine dogs.
  • Nine dogs were diagnosed with cranial mediastinal carcinomas.
  • Based on histological and immunohistochemical analysis, four dogs were diagnosed with ectopic follicular cell thyroid carcinomas, one dog with ectopic medullary cell thyroid carcinoma, two dogs with neuroendocrine carcinomas and two dogs with anaplastic carcinomas.
  • Three dogs had metastasis at the time of diagnosis, but none developed metastasis following surgery.
  • [MeSH-major] Carcinoma / veterinary. Dog Diseases / diagnosis. Dog Diseases / surgery. Mediastinal Neoplasms / veterinary
  • [MeSH-minor] Animals. Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / mortality. Carcinoma, Medullary / surgery. Carcinoma, Medullary / veterinary. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / mortality. Carcinoma, Neuroendocrine / surgery. Carcinoma, Neuroendocrine / veterinary. Dogs. Female. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / veterinary. Prognosis. Survival Analysis. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / mortality. Thyroid Neoplasms / surgery. Thyroid Neoplasms / veterinary. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178660.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV, Metze K, Ward LS: Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology; 2005 Oct;47(4):391-401
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
  • METHODS AND RESULTS: We evaluated 170 thyroid lesions including 148 neoplastic lesions [84 papillary carcinomas (PC), 38 follicular carcinomas (FC), 18 follicular adenomas, one hyalinizing trabecular tumour, five medullary carcinomas, two anaplastic carcinomas] and 22 non-neoplastic lesions (12 adenomatous nodules and 10 Hashimoto's thyroiditis).
  • Although the most helpful marker in terms of sensitivity and specificity for the follicular variant of PC and for FC diagnosis was HBME-1, when we consider the differentiation between cases of follicular variant of papillary carcinoma (FVPC) and FC or adenoma, in terms of percentage of positive cells, galectin-3 and CK 19 were more relevant.
  • [MeSH-major] Biomarkers, Tumor / analysis. Galectin 3 / metabolism. Keratins / metabolism. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178894.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 68238-35-7 / Keratins
  •  go-up   go-down


35. Pavelić K, Dedivitis RA, Kapitanović S, Cacev T, Guirado CR, Danić D, Radosević S, Brkić K, Pegan B, Krizanac S, Kusić Z, Spaventi S, Bura M: Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions. Mutat Res; 2006 Jul 25;599(1-2):45-57
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found higher incidence of p53 mutation and aberrant processing of FHIT mRNA in malignant tumors (papillary, follicular, medullary and anaplastic carcinomas) and in those tumors with distant metastasis.
  • The growth of p53(-)/FHIT(-) follicular carcinoma of human origin was much faster in nude mice than p53(+)/FHIT(+) follicular carcinoma, and mice had shorter survival rate.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698048.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


36. Ciampi R, Nikiforov YE: Alterations of the BRAF gene in thyroid tumors. Endocr Pathol; 2005;16(3):163-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activating point mutation of the BRAF gene resulting in V600E (previously designated as V599E) is a common event in thyroid papillary carcinoma, being found in approx 40% of this tumor.
  • It has strong association with classical papillary carcinoma and tall cell and possibly Warthin-like variants.
  • This mutation also occurs in thyroid poorly differentiated and anaplastic carcinomas, usually those containing areas of papillary carcinoma.
  • It is rare in sporadic papillary carcinomas and is more common in tumors associated with radiation exposure.
  • [MeSH-major] Carcinoma, Papillary / genetics. Point Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 2004 Aug;61(2):239-43 [15272920.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):321-30 [1695118.001]
  • [Cites] Curr Opin Cell Biol. 1997 Apr;9(2):180-6 [9069255.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Science. 2000 Oct 6;290(5489):138-41 [11021799.001]
  • [Cites] Oncogene. 2003 Sep 25;22(41):6455-7 [14508525.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):572-6 [15095090.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Science. 2000 Oct 6;290(5489):62-3 [11183150.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5167-71 [2052597.001]
  • [Cites] Mol Cell Biol. 1988 Jun;8(6):2651-4 [3043188.001]
  • [Cites] Cancer Lett. 2001 May 10;166(1):1-7 [11295280.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2867-72 [15181070.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5175-80 [15472223.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1093-103 [10741739.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1359-63 [15195111.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4280-4 [15356022.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1062-74 [11459867.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1365-8 [15001635.001]
  • [Cites] Cancer Lett. 2004 Jun 8;209(1):1-6 [15145515.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Int J Radiat Biol. 1997 Jan;71(1):1-19 [9020958.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2414-20 [15126572.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4561-7 [12907632.001]
  • [Cites] J Biol Chem. 1997 Feb 14;272(7):4378-83 [9020159.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):355-64 [15188460.001]
  • [Cites] Endocr Pathol. 2005 Summer;16(2):99-105 [16199894.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 [12697856.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4238-45 [15899815.001]
  • [Cites] Curr Opin Cell Biol. 2000 Apr;12(2):217-21 [10712918.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7436-40 [15273715.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):94-101 [15630448.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1988 Jan;114(1):40-4 [3334817.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4393-7 [12970315.001]
  • [Cites] Int J Cancer. 1999 Jan 5;80(1):32-8 [9935226.001]
  • [Cites] Cancer. 1972 Jul;30(1):113-27 [5040735.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4267-71 [15356020.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2761-5 [15102681.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] Cancer. 1978 Jun;41(6):2267-75 [657091.001]
  • (PMID = 16299399.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA88041
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / A Kinase Anchor Proteins; 0 / AKAP9 protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / Cytoskeletal Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Number-of-references] 45
  •  go-up   go-down


37. Maeda I, Takano T, Yoshida H, Matsuzuka F, Amino N, Miyauchi A: Tensin3 is a novel thyroid-specific gene. J Mol Endocrinol; 2006 Feb;36(1):R1-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The decrease was even more evident in two anaplastic carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16461921.001).
  • [ISSN] 0952-5041
  • [Journal-full-title] Journal of molecular endocrinology
  • [ISO-abbreviation] J. Mol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Microfilament Proteins; 0 / RNA, Messenger; 0 / tensins
  • [Number-of-references] 21
  •  go-up   go-down


38. Russo D, Bisca A, Celano M, Talamo F, Arturi F, Scipioni A, Presta I, Bulotta S, Ferretti E, Filetti S, Scaloni A, Damante G, Tell G: Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cells. J Endocrinol Invest; 2005 Feb;28(2):137-44
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nuclear extracts from the well differentiated TPC-1 (from papillary carcinoma) and the poorly differentiated ARO (from anaplastic carcinoma) cells showed an overall similar pattern of protein expression as revealed by two-dimensional gel electrophoresis analysis.
  • A similar expression pattern of nuclear Mn-SOD was detected by immunohistochemistry in human thyroid tumors, with the lowest or absent detection in anaplastic carcinomas.
  • [MeSH-major] Carcinoma / enzymology. Cell Nucleus / enzymology. Proteomics. Superoxide Dismutase / metabolism. Thyroid Neoplasms / enzymology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / enzymology. Adenocarcinoma, Follicular / pathology. Blotting, Western. Carcinoma, Papillary / enzymology. Carcinoma, Papillary / pathology. Cell Line, Tumor. Fluorescent Antibody Technique. Humans. Immunohistochemistry. In Vitro Techniques. Tissue Distribution

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Free Radic Biol Med. 1996;21(3):335-48 [8855444.001]
  • [Cites] Cancer Lett. 2002 Aug 8;182(1):69-74 [12175525.001]
  • [Cites] Technol Cancer Res Treat. 2002 Aug;1(4):257-62 [12625784.001]
  • [Cites] Thyroid. 2001 May;11(5):407-14 [11396699.001]
  • [Cites] Mol Cell Endocrinol. 2002 Aug 30;194(1-2):71-6 [12242029.001]
  • [Cites] FEBS Lett. 1995 Aug 14;370(1-2):69-74 [7649306.001]
  • [Cites] J Mol Endocrinol. 2000 Jun;24(3):383-90 [10828831.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Nat Genet. 2003 Mar;33 Suppl:238-44 [12610533.001]
  • [Cites] Antioxid Redox Signal. 2001 Jun;3(3):361-73 [11491650.001]
  • [Cites] Oncogene. 1995 May 18;10(10):1989-2000 [7761099.001]
  • [Cites] Curr Opin Mol Ther. 2001 Dec;3(6):538-45 [11804268.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):908-11 [2914297.001]
  • [Cites] Antioxid Redox Signal. 2001 Jun;3(3):461-72 [11491657.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1297-303 [12649190.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jan;33(1):6-9 [12604716.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):26044-50 [11352910.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2206-12 [8156527.001]
  • [Cites] Thyroid. 2001 Jan;11(1):41-6 [11272096.001]
  • [Cites] J Endocrinol Invest. 2001 Mar;24(3):RC10-2 [11314755.001]
  • [Cites] Endocrinology. 1989 Oct;125(4):1783-8 [2551628.001]
  • [Cites] Cancer Lett. 1996 Dec 3;109(1-2):231-5 [9020926.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1495-502 [11076659.001]
  • [Cites] Virology. 1987 Nov;161(1):62-72 [2823470.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3113-7 [8464931.001]
  • [Cites] Proteomics. 2003 Apr;3(4):440-60 [12687612.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Prostate. 1998 May 15;35(3):221-33 [9582091.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 Dec;129(6):573-8 [7509102.001]
  • [Cites] J Biol Chem. 1998 Sep 25;273(39):25062-72 [9737963.001]
  • [Cites] Proteomics. 2002 Jun;2(6):706-12 [12112852.001]
  • [Cites] Free Radic Biol Med. 1988;5(5-6):377-85 [2855738.001]
  • [Cites] Horm Metab Res. 1997 Jul;29(7):351-4 [9288568.001]
  • [Cites] FEBS Lett. 1997 Oct 13;416(1):69-71 [9369235.001]
  • [Cites] J Pathol. 1993 Mar;169(3):341-5 [8492227.001]
  • (PMID = 15887859.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


39. Klekner A, Varga I, Bognár L, Hutóczki G, Kenyeres A, Tóth J, Hanzély Z, Scholtz B: [Extracellular matrix of cerebral tumors with different invasiveness]. Ideggyogy Sz; 2010 Jan 30;63(1-2):38-43
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Contrarily, brain metastases of anaplastic carcinomas are well-circumscribed intracerebral lesions that can be easily exstirpated in most cases.
  • [MeSH-minor] Aged. Brevican. Chondroitin Sulfate Proteoglycans / analysis. Female. Humans. Immunohistochemistry. Lectins, C-Type / analysis. Lung Neoplasms / pathology. Male. Matrix Metalloproteinase 2 / analysis. Matrix Metalloproteinase 9 / analysis. Middle Aged. Neoplasm Invasiveness. Nerve Tissue Proteins / analysis. Neuregulins / analysis. Polymerase Chain Reaction. RNA, Messenger / analysis. Syndecans / analysis. Tenascin / analysis. Versicans / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20420122.001).
  • [ISSN] 0019-1442
  • [Journal-full-title] Ideggyógyászati szemle
  • [ISO-abbreviation] Ideggyogy Sz
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / BCAN protein, human; 0 / Biomarkers, Tumor; 0 / Brevican; 0 / Chondroitin Sulfate Proteoglycans; 0 / Lectins, C-Type; 0 / Nerve Tissue Proteins; 0 / Neuregulins; 0 / RNA, Messenger; 0 / Syndecans; 0 / Tenascin; 0 / neuroglycan C, human; 126968-45-4 / Versicans; 148684-98-4 / NCAN protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


40. Bergmann F, Esposito I, Michalski CW, Herpel E, Friess H, Schirmacher P: Early undifferentiated pancreatic carcinoma with osteoclastlike giant cells: direct evidence for ductal evolution. Am J Surg Pathol; 2007 Dec;31(12):1919-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early undifferentiated pancreatic carcinoma with osteoclastlike giant cells: direct evidence for ductal evolution.
  • Undifferentiated (anaplastic) carcinomas of the pancreas are rare.
  • Thus, as a result from numerous histomorphologic, immunohistochemical, ultrastructural, and molecular examinations, frequently performed as single case studies, it has been concluded that undifferentiated carcinomas and osteoclastlike giant cell tumors of the pancreas originate from epithelial cells, mesenchymal cells, undifferentiated precursor cells, or stem cells.
  • However, to date, early stage tumors have not been described, most likely because of the fact that at the time of diagnosis the tumors have commonly reached advanced stages with large tumor size.
  • In this report, we present the case of an undifferentiated pancreatic carcinoma with osteoclastlike giant cells, which was incidentally detected at a very early stage in a pancreatitis specimen.
  • Therefore, we suggest that the tumor should be considered as an anaplastic variant of pancreatic ductal adenocarcinoma.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Giant Cells / pathology. Osteoclasts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Biomarkers, Tumor / analysis. Diabetes Mellitus, Type 2 / pathology. Female. Humans. Incidental Findings. Middle Aged. Neoplasms, Second Primary / metabolism. Neoplasms, Second Primary / pathology. Smoking. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043049.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. Ulisse S, Baldini E, Toller M, Marchioni E, Giacomelli L, De Antoni E, Ferretti E, Marzullo A, Graziano FM, Trimboli P, Biordi L, Curcio F, Gulino A, Ambesi-Impiombato FS, D'Armiento M: Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. Eur J Cancer; 2006 Oct;42(15):2631-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas.
  • We characterised the expression of the plasminogen activators (uPA and tPA), the uPA receptor (uPAR) and the PAs inhibitors (PAI-1 and PAI-2) in human thyroid cell lines derived from normal thyroid, follicular adenoma, follicular, papillary and anaplastic carcinomas.
  • Quantitative RT-PCR analysis showed that uPA, uPAR and PAI-1 mRNAs increased in all carcinoma cells.
  • Similar results were found in 13 papillary thyroid carcinoma (PTC) tissues which were mirrored in Western blot experiments.
  • In conclusion, thyroid carcinoma cell lines and PTC overexpress uPA, uPAR and PAI-1 and the correlation of uPA and its cognate receptor with tumour size and metastasis may suggest their potential prognostic relevance in thyroid cancer.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Neoplasm Proteins / metabolism. Plasminogen Activators / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Humans. Neoplasm Metastasis. Prognosis. RNA, Messenger / metabolism. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Urokinase-Type Plasminogen Activator / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928445.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.21.- / Plasminogen Activators; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


42. De Vico G, Maiolino P, Cataldi M, Mazzullo G, Restucci B: Nuclear morphometry in relation to lymph node status in canine mammary carcinomas. Vet Res Commun; 2007 Nov;31(8):1005-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometry in relation to lymph node status in canine mammary carcinomas.
  • The assessment of nuclear area and nuclear shape by morphometric analysis, has been investigated in 40 canine mammary carcinomas in relation to their metastatic behaviour to regional lymph-nodes.
  • Node-positive tumours included 6 simple adenocarcinomas, 10 ductular carcinomas, 2 anaplastic carcinomas and 2 carcinomas in mixed tumours; node-negative tumours included 18 adenocarcinomas %96, 10 simple adenocarcinomas, 8 complex adenocarcinomas %96, and 2 carcinomas in mixed tumours.
  • Node-positive tumours showed MNA and mean SDA values significantly higher (p<0.001) than node-negative carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ANZ J Surg. 2002 Sep;72(9):655-9 [12269918.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):990-6 [10491525.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1362-8 [9762937.001]
  • [Cites] Lab Invest. 1992 Jan;66(1):4-23 [1731148.001]
  • [Cites] Vet Pathol. 1999 Sep;36(5):423-36 [10490210.001]
  • [Cites] Vet Pathol. 1983 Mar;20(2):127-42 [6836870.001]
  • [Cites] Cancer. 1978 Oct;42(4):2025-31 [213191.001]
  • [Cites] Histopathology. 1982 May;6(3):327-39 [7095760.001]
  • [Cites] Int J Cancer. 1991 Dec 2;49(6):886-92 [1959993.001]
  • [Cites] Riv Biol. 2005 May-Aug;98(2):279-96 [16180197.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1087-94 [10613341.001]
  • [Cites] Lancet. 1982 May 29;1(8283):1210-2 [6122973.001]
  • [Cites] ANZ J Surg. 2002 Nov;72(11):786-92 [12437688.001]
  • [Cites] J Pathol. 1995 Apr;175(4):369-79 [7790990.001]
  • [Cites] Int J Cancer. 1995 Sep 27;63(1):7-12 [7558456.001]
  • (PMID = 17279466.001).
  • [ISSN] 0165-7380
  • [Journal-full-title] Veterinary research communications
  • [ISO-abbreviation] Vet. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


43. Volante M, Rapa I, Papotti M: Poorly differentiated thyroid carcinoma: diagnostic features and controversial issues. Endocr Pathol; 2008;19(3):150-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated thyroid carcinoma: diagnostic features and controversial issues.
  • Poorly differentiated thyroid carcinomas are a heterogeneous group of tumors occupying an area intermediate between well-differentiated follicular or papillary carcinoma and anaplastic carcinomas, from both a histopathogenetic and a clinical point of view.
  • Large tumor series selected on the basis of structural and/or other morphological criteria showed that poorly differentiated carcinomas have a distinct biological behavior, and the classification of these tumors into a separate group appears justified, although strict homogeneous diagnostic criteria should be achieved and widely accepted to better characterize such tumor entity.
  • Molecular data in the literature, although limited by the heterogeneous case series analyzed, identify ras alterations as the most common molecular alteration in poorly differentiated carcinomas, thus, depicting a peculiar molecular pathway in this tumor type as compared to well-differentiated follicular and papillary carcinomas.
  • The present paper aims to review the various aspects of this tumor type, from morphology to immunohistochemistry and molecular abnormalities from a practical and daily practice-oriented point of view.
  • [MeSH-major] Thyroid Neoplasms / classification. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2003 Jun;42(6):580-7 [12786894.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1466-73 [9414190.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):686-94 [8651347.001]
  • [Cites] J Clin Invest. 1993 Apr;91(4):1753-60 [8473515.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):572-6 [15095090.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):950-7 [14983490.001]
  • [Cites] Semin Diagn Pathol. 1995 Aug;12(3):249-55 [8545591.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):353-60 [12665653.001]
  • [Cites] Adv Anat Pathol. 1999 Sep;6(5):281-6 [10472380.001]
  • [Cites] Thyroid. 2000 Jan;10(1):19-23 [10691309.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):987-96 [11238046.001]
  • [Cites] Eur J Cancer. 1979 Aug;15(8):1033-41 [510341.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):310-3 [10680904.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):370-9 [11788678.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):416-23 [8293409.001]
  • [Cites] Endocr J. 2007 Apr;54(2):265-74 [17379963.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):291-301 [8434709.001]
  • [Cites] World J Surg. 2007 May;31(5):934-45 [17431717.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23(2):205-11 [9989848.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):48-56 [18484584.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Feb;66(2):224-8 [17223992.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1007-15 [12170087.001]
  • [Cites] Hum Pathol. 1984 Mar;15(3):218-28 [6141993.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1209-17 [17665497.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1256-64 [17667551.001]
  • [Cites] Diagn Mol Pathol. 1994 Mar;3(1):9-14 [8162258.001]
  • [Cites] Int J Surg Pathol. 2002 Apr;10(2):123-31 [12075405.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1902-8 [10760768.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3226-35 [12947056.001]
  • [Cites] Thyroid. 2007 Jul;17(7):639-46 [17696834.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1849-55 [6313176.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):678-85 [10366150.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1286-95 [16470605.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1478-84 [11717536.001]
  • [Cites] Pathol Int. 1996 Dec;46(12):939-46 [9110345.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):655-68 [6476195.001]
  • [Cites] Ann Anat Pathol (Paris). 1974 Apr-Jun;19(2):129-48 [4480015.001]
  • (PMID = 18766471.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


44. Zafon C, Obiols G, Castellví J, Tallada N, Baena JA, Simó R, Mesa J: Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma. Histopathology; 2007 Jan;50(2):225-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma.
  • AIMS: Rearranged during Transfection (RET)/papillary thyroid carcinoma (PTC) and p53 are two genes involved in the pathogenesis of PTC.
  • It has been suggested that RET/PTC expression is associated with higher rates of local extension and lymph node involvement, whereas p53 mutations are more frequent in poorly differentiated and anaplastic carcinomas.
  • RET/PTC expression was associated with extrathyroid extension of PTC, at diagnosis (P < 0.05).
  • [MeSH-major] Carcinoma / metabolism. Proto-Oncogene Proteins c-ret / genetics. Thyroid Neoplasms / metabolism. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222251.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human
  •  go-up   go-down


45. Miccoli P, Materazzi G, Berti P: Minimally invasive thyroidectomy in the treatment of well differentiated thyroid cancers: indications and limits. Curr Opin Otolaryngol Head Neck Surg; 2010 Apr;18(2):114-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: To summarize recent papers in the literature with respect to minimally invasive thyroidectomy and discuss indications and limits of the endoscopic/video-assisted treatment of differentiated thyroid carcinoma.
  • SUMMARY: Papillary carcinoma is the main indication for MIVAT, this cancer usually being found in normal glands of young women.
  • In contrast, for locally invasive carcinomas, lymph node metastasis or both, the procedure must be immediately converted to the conventional technique.
  • MIVAT also is not indicated for the treatment of medullary and anaplastic carcinomas.
  • Recent prospective randomized studies clearly demonstrate that MIVAT allows the same clearance to be achieved at the thyroid bed level and the same outcome as with the conventional technique, when dealing with 'low-risk' papillary carcinoma.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Minimally Invasive Surgical Procedures / methods. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20182356.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


46. Sawai H, Okada Y, Funahashi H, Matsuo Y, Takeyama H, Manabe T: Anaplastic carcinoma of the pancreas with squamous features: report of a case and immunohistochemical study. Med Sci Monit; 2005 Nov;11(11):CS65-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma of the pancreas with squamous features: report of a case and immunohistochemical study.
  • BACKGROUND: Anaplastic carcinomas of the pancreas are rare aggressive tumors with survival measurable in weeks.
  • Many terms have been applied used to describe these tumors, and anaplastic foci are identified in ductal adenocarcinomas and in ectopic pancreata, but are not the dominant pattern of growth.
  • We herein present our experience with a case of anaplastic carcinoma of the pancreas with squamous features in order that allowed us to delineate the clinicopathologic and immunohistochemical features of this rare entity.
  • Histopathologically, anaplastic tumor cells showed focal ductal and squamous features infiltrated into pancreatic parenchyma, extrapancreatic fatty tissue, and stomach.
  • Although immunoreactivity against p53 was negative, strong positive immunostaining for proliferating cell nuclear antigen and interleukin-1 receptor type I (IL-1RI) was observed in a the majority of tumor cells, while the alpha6 integrin subunit was predominantly strong expressed in the adenocarcinomatous lesion.
  • CONCLUSIONS: Our immunohistochemical studies suggested that the prognosis of the case with anaplastic carcinoma presented here would be poor, due to the strong expression of integrins and IL-1RI.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Integrins / analysis. Pancreatic Neoplasms / diagnosis. Receptors, Interleukin-1 / analysis
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / diagnosis. Fatal Outcome. Humans. Immunohistochemistry. Male. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258403.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Integrins; 0 / Receptors, Interleukin-1
  •  go-up   go-down


47. Ito Y, Motoo Y, Yoshida H, Iovanna JL, Nakamura Y, Kuma K, Miyauchi A: High level of tumour protein p53-induced nuclear protein 1 (TP53INP1) expression in anaplastic carcinoma of the thyroid. Pathology; 2006 Dec;38(6):545-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of tumour protein p53-induced nuclear protein 1 (TP53INP1) expression in anaplastic carcinoma of the thyroid.
  • All 39 (20 minimally invasive and 19 widely invasive) follicular carcinomas and 20 adenomas were negative for or expressed only low levels of TP531NP1 except for one widely invasive follicular carcinoma.
  • Of 100 papillary carcinomas, only four (4%) expressed high levels of TP531NP1, and the remaining 96 (96%) were classified into the low group.
  • There were no significant relationships between TP531NP1 expression and clinicopathological features of papillary carcinoma.
  • However, 36 of the 38 (94.7%) anaplastic carcinomas expressed high levels of TP531NP1 and the incidence was significantly higher (p<0.0001) than that in other neoplasms.
  • CONCLUSIONS: These findings suggest that TP531NP1 plays a significant role in the progression of anaplastic carcinoma or contributes to anaplastic transformation from papillary or follicular carcinoma, which is in sharp contrast to findings in previous in vitro and in vivo studies.
  • [MeSH-major] Carcinoma / metabolism. Carrier Proteins / metabolism. Heat-Shock Proteins / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Carcinoma, Papillary / pathology. Carcinoma, Papillary, Follicular / metabolism. Carcinoma, Papillary, Follicular / pathology. Gene Expression Regulation, Neoplastic. Humans

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393983.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Heat-Shock Proteins; 0 / TP53INP1 protein, human
  •  go-up   go-down


48. Miccoli P, Minuto MN, Berti P, Materazzi G: Update on the diagnosis and treatment of differentiated thyroid cancer. Q J Nucl Med Mol Imaging; 2009 Oct;53(5):465-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the diagnosis and treatment of differentiated thyroid cancer.
  • Thus, together with small follicular lesions, "low risk" papillary carcinoma will result the main indication for MIVAT, being this small cancer usually harboured in normal glands of young females.
  • On the other hand, in case of locally invasive carcinomas and/or lymph node metastasis the procedure must be immediately converted to the conventional technique.
  • MIVAT also is not indicated for the treatment of medullary and anaplastic carcinomas.
  • Recent prospective randomized studies clearly demonstrate that MIVAT allows achieving same clearance at the thyroid bed level and same outcome as conventional technique, when dealing with "low risk" papillary carcinoma.
  • [MeSH-major] Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19910899.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 26
  •  go-up   go-down


49. Vaiman M, Olevson Y, Habler L, Kessler A, Zehavi S, Sandbank J: Diagnostic value of estrogen receptors in thyroid lesions. Med Sci Monit; 2010 Jul;16(7):BR203-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL/METHODS: Immunohistochemical stains were performed for both ERalpha and ERbeta, for evaluation of immunoreactivity in 296 thyroid tissue samples that consisted of 150 goiters, 90 papillary carcinomas, 19 follicular adenomas, 15 Hurtle cell adenomas, 6 Hashimoto thyroiditis, 5 anaplastic carcinomas, 4 medullary carcinomas, 4 follicular carcinomas, 2 Hurtle cell carcinomas, and 1 squamous cell carcinoma of the thyroid.
  • [MeSH-major] Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Goiter, Nodular / diagnosis. Thyroid Gland / metabolism. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20581768.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta
  •  go-up   go-down


50. Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, Nupponen NN, Franssila K, Joensuu H: MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol; 2005 Apr;29(4):544-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma.
  • Activating mutations affecting the MET receptor tyrosine kinase are present in several types of human cancer, particularly in papillary renal cell carcinoma.
  • Papillary thyroid carcinomas commonly express high levels of MET mRNA and protein, suggesting that increased MET signaling may be of importance in the molecular pathogenesis of differentiated thyroid carcinoma.
  • To evaluate the role of MET mutations in thyroid carcinoma, we screened MET exons 2 to 21 for mutations in sporadic papillary, follicular, medullary, and anaplastic thyroid carcinomas using denaturing high-performance chromatography.
  • A missense MET sequence alteration T1010I, located in exon 14 encoding for the juxtamembrane domain of MET, was found in 6 (6%) of the 104 thyroid carcinomas examined, whereas all 92 goiter samples had wild-type exon 14 (P = 0.031).
  • Three (6%) of the 53 papillary, 2 (10%) of the 21 follicular, 1 (8%) of the 13 medullary, and none of the 17 anaplastic carcinomas studied had MET(T1010I).
  • We conclude that MET(T1010I) sequence alteration is relatively frequent in differentiated thyroid carcinoma.
  • [MeSH-major] Carcinoma / genetics. Germ-Line Mutation. Proto-Oncogene Proteins / genetics. Receptors, Growth Factor / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Aged. Biomarkers, Tumor / metabolism. Carcinoma, Medullary / genetics. Carcinoma, Medullary / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Chromatography, High Pressure Liquid. DNA Mutational Analysis. DNA Primers / chemistry. DNA, Neoplasm / analysis. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Polymerase Chain Reaction. Proto-Oncogene Proteins c-met

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767811.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


51. Klagge A, Krause K, Schierle K, Steinert F, Dralle H, Fuhrer D: Somatostatin receptor subtype expression in human thyroid tumours. Horm Metab Res; 2010 Apr;42(4):237-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the mRNA expression of SSTR1-5 in benign and malignant epithelial thyroid tumours [20 cold thyroid nodules (CTNs), 20 toxic thyroid nodules (TTNs), 20 papillary, 20 follicular, and 5 anaplastic carcinomas (PTCs, FTCs, ATCs, respectively)] and compared them to normal surrounding thyroid tissues.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20094970.001).
  • [ISSN] 1439-4286
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Somatostatin
  •  go-up   go-down


52. King AD, Yeung DK, Ahuja AT, Tse GM, Chan AB, Lam SS, van Hasselt AC: In vivo 1H MR spectroscopy of thyroid carcinoma. Eur J Radiol; 2005 Apr;54(1):112-7
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo 1H MR spectroscopy of thyroid carcinoma.
  • To determine if proton magnetic resonance spectroscopy (1H MRS) of thyroid carcinoma is feasible and to determine if 1H MRS spectra of malignant tumors differ from that of normal thyroid tissue.
  • Spectra acquired from six primary tumors (three anaplastic carcinomas, two papillary carcinomas and one follicular carcinoma) and two nodes (two papillary carcinoma metastases) were analyzed in the time-domain using a non-linear least squares fitting algorithm with incorporation of prior knowledge.
  • Choline (3.2 ppm) was identified in all solid carcinomas with a mean choline/creatine of 4.3 at TE 136 ms and 5.4 at TE 272 ms.
  • Ratios for malignant tumors at TE 136 ms ranged from 1.6 in well differentiated follicular carcinoma to 9.4 in anaplastic carcinoma.
  • [MeSH-major] Carcinoma / diagnosis. Magnetic Resonance Spectroscopy / methods. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Choline / metabolism. Creatine / metabolism. Diagnosis, Differential. Female. Humans. Least-Squares Analysis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15797300.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


53. Tseleni-Balafouta S, Gakiopoulou H, Fanourakis G, Voutsinas G, Balafoutas D, Patsouris E: Tenascin-C protein expression and mRNA splice variants in thyroid carcinoma. Exp Mol Pathol; 2006 Apr;80(2):177-82
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tenascin-C protein expression and mRNA splice variants in thyroid carcinoma.
  • Normal and non-neoplastic tissues were devoid of Tn-C, as well as follicular neoplasms, Huerthle-cell and anaplastic carcinomas.
  • Most papillary carcinomas showed a focally intensive extracellular staining, localized in the connective tissue stroma, whereas most medullary carcinomas showed a staining in the connective tissue but also in intracellular location mainly.
  • In conclusion, Tn-C re-expression has been observed in papillary and medullary thyroid carcinomas with different staining patterns accompanied by the prevalence of different mRNA splice variants in cell cultures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259977.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tenascin
  •  go-up   go-down


54. Malle D, Valeri RM, Pazaitou-Panajiotou K, Kiziridou A, Vainas I, Destouni C: Use of a thin-layer technique in thyroid fine needle aspiration. Acta Cytol; 2006 Jan-Feb;50(1):23-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Our cases included 279 adenomatoid nodules, 15 cases of Hashimoto thyroiditis, 45 follicular neoplasms, 14 Hürthle cell tumors, 58 papillary carcinomas and 1 5 anaplastic carcinomas.
  • CONCLUSION: Thin-layer cytology improves the diagnostic accuracy of thyroid FNA and offers the possibility of performing new techniques, such as immunocytochemistry, on the same sample in order to detect malignancy as well as the type and origin of thyroid gland neoplasms.
  • [MeSH-major] Adenoma / diagnosis. Adenoma, Oxyphilic / diagnosis. Carcinoma / diagnosis. Hashimoto Disease / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Humans. Immunohistochemistry. Staining and Labeling. Thyroid Nodule / diagnosis. Thyroid Nodule / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Cytol. 2006 Jan-Feb;50(1):3-4 [16514833.001]
  • (PMID = 16514836.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Albores-Saavedra J, Hernandez M, Sanchez-Sosa S, Simpson K, Angeles A, Henson DE: Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroglobulin inclusions. Am J Surg Pathol; 2007 May;31(5):729-36
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroglobulin inclusions.
  • We describe the histologic variants of papillary and follicular carcinomas associated with 109 spindle and giant cell carcinomas (SGCC) of the thyroid and determine the incidence of rhabdoid and thyroglobulin inclusions in these tumors.
  • In addition, we searched for rhabdoid and thyroglobulin inclusions in 120 papillary carcinomas (PC) (all 15 variants included), 23 differentiated follicular carcinomas (DFC), (6 with insular pattern), 6 poorly differentiated follicular carcinomas (PDFC) and 34 follicular adenomas (FA).
  • The following differentiated thyroid carcinomas coexisted with SGCC: 51 (46.8%) PC, (34 conventional type, 14 tall cell variant and 3 follicular variant), 6 (5.5%) DFC, 1 follicular carcinoma with insular pattern (0.9%), and 3 oncocytic carcinomas (2.8%).
  • Our findings support the hypothesis that most SGCC result from dedifferentiation or anaplastic transformation although the mechanisms that underlie this transformation remain unknown.
  • The finding that only 1 (0.9%) SGCC was associated with follicular carcinoma with insular pattern contradicts the opinion that this tumor occupies an intermediate position between differentiated and anaplastic carcinomas.
  • Rhabdoid features are markers of PDFC and SGCC while thyroglobulin inclusions are markers of FA and differentiated thyroid carcinomas with follicular phenotype.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Giant Cell / pathology. Carcinoma, Papillary, Follicular / pathology. Inclusion Bodies / pathology. Rhabdoid Tumor / pathology. Thyroglobulin / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460457.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


56. Collini P, Mattavelli F, Spinelli C, Massimino M: Treatment of sporadic nonmedullary thyroid carcinomas in pediatric age. Expert Rev Anticancer Ther; 2007 Jan;7(1):23-30
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of sporadic nonmedullary thyroid carcinomas in pediatric age.
  • Nonmedullary thyroid carcinomas are rare malignancies in pediatric ages.
  • The vast majority of them are papillary carcinomas with an overall survival of approximately 100%.
  • Their outcome is independent of strong prognostic factors of adults, such as papillary carcinoma histological subtype, invasion into soft tissue of the neck, presence and site of distant metastases, relapse and type of surgery.
  • In these ages, follicular carcinomas and poorly differentiated carcinomas are exceptional.
  • Undifferentiated (anaplastic) carcinomas are practically absent.
  • In most institutions, the therapy of choice for all pediatric thyroid carcinomas is the radical approach, aimed at the eradication at diagnosis of all clinical and subclinical neoplastic foci, both at thyroid, lymph node and distant level.
  • Recently, owing also to the high sensitivity to hormonal manipulation shown by pediatric papillary carcinomas, a conservative approach has been proposed for selected cases, consisting of the removal of only the grossly detectable disease followed by thyroid-stimulating hormone-suppressive hormonal therapy to control subclinical disease.
  • Today, the existence of two therapeutic approaches, radical versus conservative therapy, should be considered whenever treating a child or adolescent with a nonmedullary thyroid carcinoma.
  • The future tasks include the stratification of thyroid carcinomas into low- and high-risk cases, also including their molecular alterations and the possibility of a molecularly targeted therapy against tyrosine kinases involved in the pathogenesis of thyroid carcinomas.
  • [MeSH-major] Carcinoma, Papillary / surgery. Thyroid Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17187518.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 28
  •  go-up   go-down


57. Hassan I, Osei-Agymang T, Fernández ED, Behr T, Barth P, Ramaswamy A, Mueller HH, Zielke A, Rothmund M: Does fine-needle aspiration cytology optimize the surgical management of thyroid disorders in endemic goiter region? Endocr Pathol; 2008;19(1):34-9
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 15 patients (15%), carcinomas were found in the postoperative histopathological diagnosis (including four follicular carcinomas).
  • In the 48 patients of FNAC groups 3 and 4, nine carcinomas (18.7%) were found (including four follicular carcinomas).
  • In the 28 patients of groups 1 and 2, there was only one papillary carcinoma (3.5%).
  • In the 24 patients of group 0, there were two papillary, two follicular, and one anaplastic carcinomas (total of 20.8%).
  • CONCLUSIONS: Despite the high prevalence of carcinoma in an endemic goiter region, FNAC disappointed its diagnostic expectation.
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Carcinoma / pathology. Carcinoma / surgery. Female. Germany / epidemiology. Humans. Male. Middle Aged. Prevalence. Prospective Studies. Sensitivity and Specificity. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Dec 25;90(6):357-63 [11156519.001]
  • [Cites] Postgrad Med. 1991 Jul;90(1):183-7, 190 [2062755.001]
  • [Cites] Diagn Cytopathol. 1997 Oct;17(4):239-47 [9316777.001]
  • [Cites] Arch Surg. 1989 Oct;124(10):1201-4; discussion 1204-5 [2802984.001]
  • [Cites] Rev Med Chil. 2000 Apr;128(4):405-10 [10962858.001]
  • [Cites] Br J Surg. 2003 Jun;90(6):755-8 [12808628.001]
  • [Cites] J Clin Pathol. 1992 May;45(5):391-5 [1597516.001]
  • [Cites] Acta Cytol. 2001 Sep-Oct;45(5):669-74 [11575641.001]
  • [Cites] Acta Endocrinol (Copenh). 1989 Aug;121(2):197-202 [2773619.001]
  • [Cites] JAMA. 1994 Mar 2;271(9):703-7 [8309035.001]
  • [Cites] Endocr Rev. 1984 Spring;5(2):185-99 [6203730.001]
  • [Cites] Ann Acad Med Singapore. 1998 Mar;27(2):196-9 [9663309.001]
  • [Cites] Am J Surg. 1993 Oct;166(4):350-2 [8214290.001]
  • [Cites] Radiobiol Radiother (Berl). 1987;28(5):622-6 [3441611.001]
  • [Cites] Aust N Z J Surg. 1990 Nov;60(11):879-81 [2241647.001]
  • [Cites] Nuklearmedizin. 2006;45(5):201-5 [17043730.001]
  • [Cites] Endocr Pathol. 2006 Spring;17(1):61-5 [16760581.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):130-4 [2049733.001]
  • [Cites] Eur J Surg. 2001 Sep;167(9):656-61 [11759733.001]
  • [Cites] Ear Nose Throat J. 2002 Mar;81(3):151-4 [11913059.001]
  • [Cites] Eur J Endocrinol. 1998 Jan;138(1):30-1 [9461311.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • (PMID = 18202924.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Ersoz S, Sert H, Yandi M, Erem C, Mungan S, Ersoz HO, Cobanoglu U, Hacihasanoglu A: The significance of Galectin-3 expression in the immunocytochemical evaluation of thyroid fine needle aspiration cytology. Pathol Oncol Res; 2008 Dec;14(4):457-60
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to evaluate the significance of immunohistochemical expression of Galectin-3 in the differential diagnosis of benign and malignant thyroid nodules.
  • Three cases of five follicular carcinomas had positive staining for Galectin-3, while two had not.
  • Five cases of six papillary carcinomas had positive staining for Galectin-3, while one case (the case with a papillary microcarcinoma) had not.
  • The single cases with medullary and anaplastic carcinomas were negative for Galectin-3.
  • Galectin-3 could be used as a supplementary marker for cytological diagnosis.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Papillary / diagnosis. Biomarkers, Tumor / analysis. Galectin 3 / biosynthesis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 1993;9(3):345-50 [8519202.001]
  • [Cites] Thyroid. 1998 May;8(5):377-83 [9623727.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):449-53 [14585093.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Mayo Clin Proc. 1997 Oct;72(10):913-6 [9379692.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2637-41 [9703921.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3267-71 [7542167.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Pathol Annu. 1989;24 Pt 1:161-98 [2654836.001]
  • [Cites] Acta Cytol. 2006 Jan-Feb;50(1):28-34 [16514837.001]
  • [Cites] Oncogene. 1992 Dec;7(12):2507-11 [1461653.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3494-502 [10550147.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4530-4 [8813152.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2475-84 [10357421.001]
  • (PMID = 18415710.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


59. Du ZX, Wang HQ, Zhang HY, Gao DX: Involvement of glyceraldehyde-3-phosphate dehydrogenase in tumor necrosis factor-related apoptosis-inducing ligand-mediated death of thyroid cancer cells. Endocrinology; 2007 Sep;148(9):4352-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TNF-related apoptosis-inducing ligand (TRAIL) is cytotoxic to most thyroid cancer cell lines, including those originating from anaplastic carcinomas, implying TRAIL as a promising therapeutic agent against thyroid cancers.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17540725.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 1.2.1.9 / Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+); EC 3.4.22.- / Caspase 3
  •  go-up   go-down


60. Andry G, Willemse E, Digonnet A, De Keyser C, Vandevelde L, Plat L, Larsimont D, Muylle K, Lemort M: [Thyroid cancers]. Rev Med Brux; 2009 Sep;30(4):279-86
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anaplastic carcinomas are very aggressive, no therapeutic solution, excepted in some selected case for when radical surgery is possible (flap reconstruction) followed by chemoradiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Med Brux. 2009 Sep-Oct;30(5):482
  • (PMID = 19899374.001).
  • [ISSN] 0035-3639
  • [Journal-full-title] Revue médicale de Bruxelles
  • [ISO-abbreviation] Rev Med Brux
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Recombinant Proteins; 9002-71-5 / Thyrotropin
  •  go-up   go-down


61. Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, De Vathaire F, Schlumberger M: Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid; 2007 Jul;17(7):639-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification.
  • OBJECTIVE: Poorly differentiated follicular thyroid carcinoma (PDFC) is a tumor of follicular cell origin with attributes intermediate between well-differentiated carcinomas and anaplastic carcinomas, but neither a clear histological description nor an established definition of prognostic indicators are available.
  • An older age at the time of diagnosis and a larger tumor size were associated with an increased risk of distant metastases and of cancer-related death.
  • CONCLUSION: PDFC has a more aggressive behavior than well-differentiated carcinomas; prognosis is related to indicators that are also relevant in patients with well-differentiated carcinomas.


62. Aichler M, Algül H, Behne D, Hölzlwimmer G, Michalke B, Quintanilla-Martinez L, Schmidt J, Schmid RM, Brielmeier M: Selenium status alters tumour differentiation but not incidence or latency of pancreatic adenocarcinomas in Ela-TGF-alpha p53+/ mice. Carcinogenesis; 2007 Sep;28(9):2002-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic carcinoma has so far not been tested as an end-point in such studies.
  • Also, the mean latency of pancreatic carcinomas (n = 83) was not influenced (464 versus 466 days).
  • A highly significant difference in the differentiation grade of the pancreatic tumours was evident between the two groups: selenium-deficient mice (n = 33) developed predominantly undifferentiated anaplastic carcinomas (26 anaplastic versus 7 differentiated), whereas in the selenium-supplemented group (n = 50) mainly well-differentiated carcinomas were detected (20 anaplastic versus 30 differentiated).

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638921.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Transcription Factors; 0 / Transforming Growth Factor alpha; 0 / Tumor Suppressor Protein p53; 0 / elongin; H6241UJ22B / Selenium
  •  go-up   go-down


63. Martinez Hoyos J, Ferraro A, Sacchetti S, Keller S, De Martino I, Borbone E, Pallante P, Fedele M, Montanaro D, Esposito F, Cserjesi P, Chiariotti L, Troncone G, Fusco A: HAND1 gene expression is negatively regulated by the High Mobility Group A1 proteins and is drastically reduced in human thyroid carcinomas. Oncogene; 2009 Feb 12;28(6):876-85
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HAND1 gene expression is negatively regulated by the High Mobility Group A1 proteins and is drastically reduced in human thyroid carcinomas.
  • We have also investigated HAND1 expression in human thyroid carcinoma cell lines and tissues, in which HMGA proteins are overexpressed, with respect to normal thyroid; an inverse correlation between HMGA1 and HAND1 expression was found in all thyroid tumor histotypes.
  • A correlation between HAND1 gene repression and promoter hypermethylation was found in anaplastic carcinomas but not in other thyroid tumor histotypes.
  • Therefore, we can hypothesize that HMGA1 overexpression plays a key role on HAND1 silencing in differentiated thyroid carcinomas and that promoter hypermethylation occurs in later stages of thyroid tumor progression.
  • Finally, the restoration of the HAND1 gene expression reduces the clonogenic ability of two human thyroid carcinoma-derived cell lines, suggesting that HAND1 downregulation may have a role in the process of thyroid carcinogenesis.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Carcinoma / metabolism. Gene Expression Regulation, Neoplastic. HMGA1a Protein / metabolism. High Mobility Group Proteins / metabolism. Thyroid Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19060921.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Hand1 protein, mouse; 0 / High Mobility Group Proteins; 0 / helix-loop-helix protein, eHAND; 124544-67-8 / HMGA1a Protein
  •  go-up   go-down


64. Jakab C, Rusvai M, Szabó Z, Szabára A, Kulka J: Expression of the claudin-4 molecule in benign and malignant canine hepatoid gland tumours. Acta Vet Hung; 2009 Dec;57(4):463-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesions studied included normal hepatoid glands (n = 10), nodular hyperplasias (n = 10), adenomas (n = 12), epitheliomas (n = 15), differentiated carcinomas (n = 15) and anaplastic carcinomas (n = 15).
  • The numerical score for cellular expression of claudin-4 was higher in differentiated carcinomas than in epitheliomas, but moderately lower than in adenomas.
  • The anaplastic, poorly differentiated hepatoid gland carcinomas showed an overexpression of claudin-4.
  • These results suggest that low claudin-4 expression in epitheliomas is a molecular characteristic indicative of increasing cellular disorientation, detachment motility and invasion by tumour cells, and claudin-4 seems to be helpful in distinguishing undifferentiated carcinomas from differentiated carcinomas and epitheliomas of the hepatoid gland.
  • In addition, claudin-4 can help distinguish epithelioma from differentiated carcinoma of the canine hepatoid gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19897451.001).
  • [ISSN] 0236-6290
  • [Journal-full-title] Acta veterinaria Hungarica
  • [ISO-abbreviation] Acta Vet. Hung.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Claudin-4; 0 / Membrane Proteins
  •  go-up   go-down


65. Festa M, Petrella A, Alfano S, Parente L: R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway. Int J Cancer; 2009 Jun 1;124(11):2728-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway.
  • Among thyroid carcinomas, highly aggressive undifferentiated or anaplastic carcinomas still await effective therapeutic strategies.
  • These results demonstrate that undifferentiated thyroid carcinoma cells can be effectively killed by a combination treatment of subtoxic doses of R-roscovitine and TRAIL.
  • The combination of R-roscovitine and TRAIL may represent a novel approach to the treatment of anaplastic thyroid carcinomas resistant to conventional chemotherapy.
  • [MeSH-minor] Active Transport, Cell Nucleus / drug effects. Carcinoma. Caspase 3 / metabolism. Cell Division / drug effects. Cell Line, Tumor. G2 Phase / drug effects. Humans. Receptors, TNF-Related Apoptosis-Inducing Ligand / analysis. bcl-X Protein / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19230027.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / NF-kappa B; 0 / Purines; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / bcl-X Protein; 0 / roscovitine; EC 2.7.11.10 / I-kappa B Kinase; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


66. Lazăr D, Tăban S, Ardeleanu C, Dema A, Sporea I, Cornianu M, Lazăr E, Vernic C: The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients' survival. Rom J Morphol Embryol; 2008;49(4):459-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of our study is to investigate the immunohistochemical expression of E-cadherin in gastric carcinomas and in surrounding mucosa (normal or with lesions of chronic atrophic gastritis, intestinal metaplasia or dysplasia).
  • Aberrant E-cadherin expression was noticed in 30 cases of gastric carcinomas (49.2%) and in 11 cases (35.5%) of epithelial dysplasia in the surrounding tissue.
  • Aberrant E-cadherin immunostainings were significantly more frequent in diffuse-type carcinomas in comparison with the intestinal-type carcinomas (82.4% vs. 31.6%) (p = 0.000491 ES).
  • Signet-ring carcinomas and anaplastic carcinomas presented a high-proportion of aberrant immunostainings (82.4% and 100%), as well as poor differentiated carcinomas (61.5%).
  • Carcinomas with distant metastasis presented significantly more aberrant immunostainings than those without metastasis (71.4% vs. 42.6%).
  • CONCLUSIONS: In gastric carcinomas and areas of epithelial dysplasia, aberrant E-cadherin expression was significantly more frequent in comparison with the surrounding normal mucosa (p<0.001 ES).
  • Our data suggest a strong correlation between Lauren's classification of gastric carcinomas and E-cadherin immunohistochemical expression.
  • [MeSH-major] Cadherins / metabolism. Carcinoma / mortality. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050793.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


67. Munson L, Moresco A: Comparative pathology of mammary gland cancers in domestic and wild animals. Breast Dis; 2007;28:7-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The more common morphologic types of mammary cancer in canids and felids include tubulopapillary, solid, cribriform, comedo and anaplastic carcinomas.
  • Dogs also develop complex carcinomas, which likely evolve from the complex adenomas or mixed tumors that are so common in this species and are promoted by exogenous progesterone treatment.

  • MedlinePlus Health Information. consumer health - Pet Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057539.001).
  • [ISSN] 0888-6008
  • [Journal-full-title] Breast disease
  • [ISO-abbreviation] Breast Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Contraceptive Agents, Female; 0 / Gonadal Steroid Hormones; 0 / Progestins; 0 / Receptors, Steroid
  • [Number-of-references] 126
  •  go-up   go-down


68. Ruangpratheep C, Lohachittranond C, Poonpracha T, Punyarit P: OCT4 expression on a case of poorly differentiated (insular) carcinoma of the thyroid gland and minireview. J Med Assoc Thai; 2005 Nov;88 Suppl 3:S281-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] OCT4 expression on a case of poorly differentiated (insular) carcinoma of the thyroid gland and minireview.
  • Poorly differentiated (insular) carcinoma of the thyroid gland is rare and defined as follicular-cell neoplasms that show limited evidence of structural follicular cell differentiation and occupy both morphologically and behaviourally an intermediate position between differentiated (follicular and papillary carcinomas) and undifferentiated (anaplastic) carcinomas.
  • Final pathological diagnoses of her mass were poorly differentiated (insular) carcinoma with lymphovascular invasion and nodular goiter.
  • The authors believe that poorly differentiated (insular) carcinoma of the thyroid gland probably develops from the remnant of thyroid stem cells and is not associated with dedifferentiation (anaplasia or loss of cellular differentiation) from nodular goiter or cells of other thyroid carcinomas.
  • However, there is only one case of immunohistochemistry of OCT4 in poorly differentiated (insular) carcinoma of the thyroid gland.
  • [MeSH-major] Carcinoma / metabolism. Octamer Transcription Factor-3 / metabolism. Thyroid Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858970.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Octamer Transcription Factor-3
  • [Number-of-references] 14
  •  go-up   go-down


69. Nucera C, Mazzon E, Caillou B, Violi MA, Moleti M, Priolo C, Sturniolo G, Puzzolo D, Cavallari V, Trimarchi F, Vermiglio F: Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia. J Endocrinol Invest; 2005 Feb;28(2):106-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increasing hgal-3 immunoexpression has been reported in several human tumors, including thyroid carcinomas, but not in benign thyroid lesions.
  • Hgal-3 immunoperoxidase reaction was carried out on 133 thyroid tissue samples obtained from 113 patients; 20 of these were normal (NT), 85 were benign thyroid lesions [20 colloid nodules (CN), 21 nodular hyperplasias (NH), 7 focal lymphocytic thyroiditis (FLT), 15 Hashimoto's thyroiditis (HT), 22 follicular adenomas (FA)], 25 differentiated carcinomas [15 papillary carcinomas (PC), 6 follicular carcinomas (FC) and 4 Hürthle cell carcinomas (HC)] and 3 anaplastic carcinomas (AC).
  • Hgal-3 cytoplasmic-perinuclear immunolocalization was observed in the majority of thyroid carcinomas and in more than half of the FA, theoretically suggesting an involvement of this protein in thyroid tumorigenesis throughout an antiapoptotic activity.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1213-7 [7862663.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):449-53 [14585093.001]
  • [Cites] Thyroid. 2003 Aug;13(8):765-70 [14558920.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] Biochemistry. 1994 Nov 29;33(47):14109-14 [7947821.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):361-7 [10956411.001]
  • [Cites] J Pathol. 1997 Jan;181(1):80-6 [9072007.001]
  • [Cites] Invasion Metastasis. 1997;17(2):101-12 [9561029.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):494-8 [12657934.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Cancer Lett. 2003 Sep 10;199(1):69-73 [12963125.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1117-23 [14614051.001]
  • [Cites] J Biol Chem. 1994 Aug 19;269(33):20807-10 [8063692.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):428-33 [10821488.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2637-41 [9703921.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1869-73 [11280740.001]
  • [Cites] J Biol Chem. 1994 Feb 11;269(6):4424-30 [8308013.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2818-26 [7773932.001]
  • [Cites] Int J Oncol. 2001 Apr;18(4):787-92 [11251175.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):710-3 [12033961.001]
  • [Cites] Anat Rec. 1995 Jun;242(2):211-9 [7668406.001]
  • [Cites] Mod Pathol. 1997 May;10(5):515-9 [9160320.001]
  • [Cites] Endocr Pathol. 2001 Fall;12(3):275-9 [11740048.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):309-12 [14999471.001]
  • [Cites] Exp Cell Res. 1995 Oct;220(2):397-406 [7556449.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6239-45 [10626818.001]
  • [Cites] Histopathology. 2002 Jan;40(1):80-7 [11903601.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):15819-27 [11839755.001]
  • [Cites] Biochem Soc Trans. 1992 May;20(2):269-74 [1397610.001]
  • [Cites] J Endocrinol Invest. 2004 Apr;27(4):311-7 [15233548.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 14;302(3):545-53 [12615069.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3494-502 [10550147.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4530-4 [8813152.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2475-84 [10357421.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3015-20 [9679965.001]
  • (PMID = 15887854.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Galectin 3
  •  go-up   go-down


70. Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macrì L, Daniele L, Oliaro A: Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg; 2009 Feb;87(2):365-71; discussion 371-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A significant difference was found between prevalence in non-small cell lung carcinomas versus neuroendocrine tumors (290 of 1,208, 24% versus 4 of 82, 5%; p = 0.0001).
  • Prevalence was similar in adenocarcinomas, squamous-cell carcinomas, and large-cell anaplastic carcinomas.
  • A not significantly better survival in the presence of TIL was observed overall (p = 0.20), becoming significant in squamous-cell carcinomas (p = 0.03).
  • In patients with stage I disease, TIL is associated with a significant survival advantage in squamous-cell carcinomas (p = 0.03).
  • The presence of TIL correlates with an improved survival in squamous cell carcinomas, particularly at early stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19161739.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


71. Heller DA, Clifford CA, Goldschmidt MH, Holt DE, Shofer FS, Smith A, Sorenmo KU: Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma. Vet Pathol; 2005 Nov;42(6):776-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma.
  • The goal of the study reported here was to determine whether a direct association between levels of COX-2 expression and tumor histologic subtype exists in canine mammary carcinoma.
  • Anaplastic carcinomas had a significantly higher COX-2 staining distribution, intensity, and index, compared with those for adenocarcinomas (P < 0.0001).
  • To the authors' knowledge, these results indicate, for the first time, a direct association between COX-2 expression and tumor histologic subtype in canine mammary carcinomas.
  • Future research directed at measuring tumor response in canine mammary carcinoma patients treated with a selective COX-2 inhibitor is indicated.
  • [MeSH-major] Adenocarcinoma / veterinary. Carcinoma / veterinary. Cyclooxygenase 2 / metabolism. Dog Diseases / enzymology. Gene Expression Regulation, Neoplastic. Mammary Neoplasms, Animal / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16301573.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


72. Rivera M, Ricarte-Filho J, Tuttle RM, Ganly I, Shaha A, Knauf J, Fagin J, Ghossein R: Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid; 2010 Oct;20(10):1085-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension.
  • BACKGROUND: The impact of varying degrees of extrathyroid extension (ETE), especially microscopic ETE (METE), on survival in thyroid carcinomas (TC) has not been well established.
  • Twelve papillary thyroid carcinomas (PTCs) without ETE and NMP were also analyzed.
  • There was a much higher frequency of poorly differentiated and anaplastic carcinomas (12/29, 41%) in patients with gross ETE than in those with METE (3/52, 6%) (p < 0.01).
  • Except for an anaplastic case, no recurrences were detected in 45 patients with METE, including 23 PTC patients followed up for a median of 10 years without radioactive iodine therapy.
  • Fifty-six cases with ETE were genotyped as follows: BRAFV600E, 39 (70%); BRAFV600E-AKT1, 1 (1.8%); NRAS, 1 (1.8%); KRAS, 1 (1.8%); RET/PTC, 3 (5%); wild type, 11 (19.6%).
  • [MeSH-minor] Carcinoma / genetics. Carcinoma, Papillary / pathology. Esophagus / pathology. Humans. Necrosis. Proto-Oncogene Proteins B-raf. Trachea / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860430.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA050706
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Other-IDs] NLM/ PMC4984786
  •  go-up   go-down


73. Horvatić Herceg G, Herceg D, Kralik M, Bence-Zigman Z, Tomić-Brzac H, Kulić A: Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study. Wien Klin Wochenschr; 2006 Oct;118(19-20):601-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.
  • PURPOSE: Higher levels of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) are linked to the poor prognosis in a variety of malignances. uPA and PAI-1 were expressed in most thyroid carcinomas, as had been measured immunohistochemically.
  • The lowest values were in adenomas (uPA=0.013 +/- 0.025 and PAI-1=2.785 +/- 1.069 ng/mg protein) and the highest in anaplastic carcinomas (uPA=8.45 +/- 2.192 and PAI-1=94.65 +/- 59.468 ng/mg protein).
  • uPA and PAI-1 were significantly higher in anaplastic vs. well-differentiated cancers (uPA P=0.014 and PAI-1 P=0.026), if extrathyroidal invasion (uPA P=0.019 and PAI-1 P=0.009) or distant metastases (uPA P=0.006 and PAI-1 P=0.003) had been present, and in tumors whose size exceeded 1 cm in diameter (uPA P=0.009 and PAI-1 P=0.035).
  • [MeSH-major] Biomarkers, Tumor / analysis. Blood Proteins / analysis. Cytosol / pathology. Thyroid Neoplasms / pathology. Urokinase-Type Plasminogen Activator / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4065-71 [8033138.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):564-73 [9028369.001]
  • [Cites] Cancer Control. 2000 May-Jun;7(3):240-5 [10832110.001]
  • [Cites] Eur J Cancer. 1980 Nov;16(11):1513-5 [6262087.001]
  • [Cites] Surgery. 1984 Dec;96(6):957-71 [6505969.001]
  • [Cites] Thyroid. 1999 Sep;9(9):913-9 [10524570.001]
  • [Cites] Am J Med. 1994 Nov;97(5):418-28 [7977430.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4629-36 [6458354.001]
  • [Cites] Eur J Cancer. 1979 Aug;15(8):1033-41 [510341.001]
  • [Cites] Laryngoscope. 2004 Mar;114(3):393-402 [15091208.001]
  • [Cites] Surgery. 2004 Sep;136(3):609-16 [15349109.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2527-30 [8168072.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):636-43 [10676647.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1746-51 [10206287.001]
  • [Cites] Thromb Haemost. 1997 Jul;78(1):285-96 [9198168.001]
  • [Cites] Lancet. 1989 Oct 28;2(8670):1049 [2572788.001]
  • [Cites] Surgery. 1987 Dec;102(6):1088-95 [3686348.001]
  • [Cites] Thyroid. 2004 Jun;14(6):453-8 [15242573.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):878-83 [9041148.001]
  • [Cites] Diagn Mol Pathol. 2004 Dec;13(4):241-6 [15538115.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1186-94 [12599224.001]
  • [Cites] Oncol Rep. 1995 Jul;2(4):525-8 [21597769.001]
  • [Cites] Cancer Control. 2000 May-Jun;7(3):229-39 [10832109.001]
  • [Cites] J Endocrinol. 2000 Nov;167(2):229-38 [11054636.001]
  • [Cites] Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8 [8256208.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):487-92 [8697395.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4671-5 [8062262.001]
  • [Cites] Adv Cancer Res. 1985;44:139-266 [2930999.001]
  • [Cites] Anticancer Res. 1996 Jan-Feb;16(1):81-9 [8615674.001]
  • [Cites] Int J Cancer. 1997 Jul 3;72(1):1-22 [9212216.001]
  • [Cites] Endocrinol Metab Clin North Am. 1990 Sep;19(3):545-76 [2261906.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6539-48 [7987854.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):724-32 [9477106.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):361-70 [7114941.001]
  • [Cites] Wien Klin Wochenschr. 1990 Apr 27;102(9):249-53 [2375111.001]
  • (PMID = 17136335.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / urokinase inhibitor; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


74. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM: Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer; 2008 Jul 1;113(1):48-56
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
  • BACKGROUND: Radioactive iodine-refractory (RAIR) 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) positive thyroid carcinomas represent the major cause of deaths from thyroid carcinomas (TC) and are therefore the main focus of novel target therapies.
  • However, to the authors' knowledge, the histology of FDG-PET-positive RAIR metastatic thyroid carcinoma has not been described to date.
  • Poorly differentiated thyroid carcinomas (PDTC) were defined on the basis of high mitotic activity (> or =5 mitoses/10 high-power fields) and/or tumor necrosis.
  • Other types of carcinomas were defined by conventional criteria.
  • Histologic characterization of the metastasis/recurrence in 70 patients revealed that 47.1% (n = 33 patients) had PDTC, 20% (n = 14 patients) had the tall cell variant (TCV) of papillary thyroid carcinoma, 22.9% (n = 16 patients) had well-differentiated papillary thyroid carcinoma (WDPTC), 8.6% (n = 6 patients) had Hurthle cell carcinoma (HCC), and 1.4% (n = 1 patient) had anaplastic carcinomas.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Copyright) 2008 American Cancer Society.
  • (PMID = 18484584.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


75. Lazăr D, Tăban S, Sporea I, Dema A, Cornianu M, Lazăr E, Goldiş A, Vernic C: Gastric cancer: correlation between clinicopathological factors and survival of patients. II. Rom J Morphol Embryol; 2009;50(2):185-94
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The analysis of the potential prognosis factors has included in this study parameters concerning the patient (sex, age), as well as parameters related with the tumor (macroscopic aspect of the tumor according to the Borrman's classification, histological type according to the WHO and Lauren's classifications, degree of tumor differentiation, tumor location, stage of disease, pT and pM parameters according to the TNM classification of AJCC/UICC).
  • We have identified five papillary adenocarcinomas (8.2%), 28 tubular adenocarcinomas (46%), 17 "signet-ring" cell carcinomas (27.8%), eight mucinous adenocarcinomas (13.1%), and three undifferentiated or anaplastic carcinomas.
  • Most gastric carcinomas examined were included in the category of poorly differentiated carcinomas (63.9%).
  • According to the Lauren's classification, we have identified 38 intestinal type gastric carcinomas (62.3%), 17 diffuse type carcinomas (27.9%), and six mixed carcinomas (9.8%).
  • CONCLUSIONS: "Signet-ring" cells carcinomas, and the anaplastic ones, prove in our study to be extremely aggressive histological forms, characterized through low rates of survival.
  • We remarked a significant correlation between the degree of tumor differentiation and survival of patients, the values recorded being significantly lower in medium and poorly differentiated carcinomas (p = 0.00871194 FS).
  • Average survival, calculated in months, is significantly lower in patients with diffuse type carcinomas (11.3 months), in comparison with patients presenting intestinal type carcinomas (20.4 months) (p = 0.0415 S).
  • [MeSH-major] Carcinoma / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434309.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


76. Sidibé el H: [Thyroid diseases in sub-Saharan Africa]. Sante; 2007 Jan-Mar;17(1):33-9
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The paucity of laboratories specializing in endocrinology and of nuclear medicine facilities, the delay in diagnosis that results in compressive or recurrent goiters, and endemic goiters are all typical in Africa.
  • Single-nodule tumors were assessed in 89 patients in Khartoum: they were found to be simple goiters in 72% of cases, follicular adenoma in 13.5%, cancer in 13.5% (with 6 of the 12 cases follicular, 5 papillary, and 1 anaplastic).
  • Thyroid cancer at Ibadan was found to be papillary carcinoma in 45.3% of cases; follicular forms were seen in 44.5% and this series includes 5% of medullary cancers (7 cases), with a mean age of 34 years.
  • Thyroid cancers in Algeria are associated with low socioeconomic status and characterized by a high prevalence of cancers discovered at an advanced stage and of anaplastic carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17897900.001).
  • [ISSN] 1157-5999
  • [Journal-full-title] Santé (Montrouge, France)
  • [ISO-abbreviation] Sante
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antithyroid Agents; 8KQ660G60G / Carbimazole
  •  go-up   go-down


77. Njim L, Moussa A, Hadhri R, Gassab I, Ben Yahia N, Mahmoudi H, Zakhama A: [Angiomatoid tumor of the thyroid gland: primitive angiosarcoma or variant of anaplastic carcinoma?]. Ann Pathol; 2008 Jun;28(3):221-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiomatoid tumor of the thyroid gland: primitive angiosarcoma or variant of anaplastic carcinoma?].
  • [Transliterated title] Tumeur angiomatoïde de la thyroïde: angiosarcome primitif ou variante du carcinome anaplasique?
  • The histogenesis of thyroid angiomatoid tumors has been controversial for many years: these tumors may be either a variant of anaplastic carcinoma, or an angiosarcoma.
  • We also discuss, through a review of the literature, the pathologic criteria that could be used to distinguish between angiosarcoma and anaplastic carcinoma of the thyroid.
  • [MeSH-major] Carcinoma / pathology. Hemangiosarcoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Keratins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18706366.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


78. Laco J, Ryska A, Celakovský P: [Anaplastic carcinoma of the thyroid gland with chondrosarcomatous component]. Cesk Patol; 2005 Jan;41(1):34-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic carcinoma of the thyroid gland with chondrosarcomatous component].
  • [Transliterated title] Anaplastický karcinom stítné zlázy s chondrosarkomatózní komponentou.
  • Fine needle aspiration cytology was performed with the conclusion of a sarcomatoid variant of anaplastic carcinoma of the thyroid gland; biopsy was recommended.
  • The diagnosis of thyroid anaplastic carcinoma with chondrosarcomatous component was established.
  • [MeSH-major] Carcinoma / pathology. Chondrosarcoma / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816122.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


79. Hommell-Fontaine J, Borda A, Ragage F, Berger N, Decaussin-Petrucci M: Nonconventional papillary thyroid carcinomas with pleomorphic tumor giant cells: a diagnostic pitfall with anaplastic carcinoma. Virchows Arch; 2010 Jun;456(6):661-70
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonconventional papillary thyroid carcinomas with pleomorphic tumor giant cells: a diagnostic pitfall with anaplastic carcinoma.
  • The presence of pleomorphic tumor giant cells in thyroid carcinomas of follicular cell origin is always worrisome for the pathologist as they first of all refer to anaplastic carcinoma, one of the most aggressive human malignancies.
  • However, non-anaplastic pleomorphic giant cells are well described in other thyroid diseases, most often benign.
  • In this paper, we describe four cases of papillary thyroid carcinoma displaying pleomorphic tumor giant cells with features that differ from those of anaplastic carcinoma.
  • Pleomorphic giant cells were admixed with the underlying thyroid carcinoma and constituted from 5% to 25% of the tumor.
  • Compared to pleomorphic giant cells of anaplastic carcinoma, they reproduced the growth pattern of the underlying carcinoma, had a low mitotic index without necrosis or inflammation, and were reactive with thyroglobulin and thyroid-specific transcription factor-1 and strongly and diffusely positive for cytokeratin AE1/AE3.
  • These cases show that pleomorphic tumor giant cells arising in papillary thyroid carcinomas do not always represent dedifferentiation and progression to anaplastic carcinoma.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Papillary / pathology. Giant Cells / pathology. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2009 Jun;37(6):455-65 [19306421.001]
  • [Cites] Endocr J. 2003 Apr;50(2):173-7 [12803237.001]
  • [Cites] Am J Surg Pathol. 1997 Nov;21(11):1261-70 [9351564.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):321-30 [1695118.001]
  • [Cites] Am J Clin Pathol. 1997 Jan;107(1):20-5 [8980362.001]
  • [Cites] Endocr Pathol. 2004 Winter;15(4):319-27 [15681856.001]
  • [Cites] Surgery. 1991 Dec;110(6):956-61; discussion 961-3 [1745983.001]
  • [Cites] Histopathology. 1994 Mar;24(3):205-10 [8200621.001]
  • [Cites] Arch Pathol Lab Med. 1978 Sep;102(9):445-7 [210736.001]
  • [Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]
  • [Cites] Acta Cytol. 2002 Sep-Oct;46(5):823-7 [12365214.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Endocr Pathol. 2006 Spring;17(1):1-18 [16760576.001]
  • [Cites] J Pathol. 1997 Jan;181(1):80-6 [9072007.001]
  • [Cites] World J Surg. 1999 Sep;23(9):975-8; discussion 978-9 [10449831.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1139-45 [11014583.001]
  • [Cites] Am J Surg Pathol. 1980 Aug;4(4):333-41 [6999920.001]
  • [Cites] Acta Cytol. 1996 Nov-Dec;40(6):1184-8 [8960026.001]
  • [Cites] Histopathology. 2002 Sep;41(3):236-43 [12207785.001]
  • [Cites] Pathol Res Pract. 2008;204(3):191-5 [18037575.001]
  • [Cites] Hum Pathol. 2008 Jul;39(7):1080-7 [18495207.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):283-292 [12114789.001]
  • [Cites] World J Surg. 2001 May;25(5):617-22 [11369989.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2637-41 [9703921.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1256-64 [17667551.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):710-3 [12033961.001]
  • [Cites] Am J Clin Pathol. 2006 Mar;125(3):399-406 [16613343.001]
  • [Cites] Surgery. 2002 Mar;131(3):245-8 [11894027.001]
  • [Cites] Hum Pathol. 2003 Jul;34(7):666-9 [12874762.001]
  • [Cites] Histopathology. 2007 Jan;50(2):225-31 [17222251.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Am J Surg Pathol. 1994 Oct;18(10):1054-64 [7522412.001]
  • [Cites] Diagn Cytopathol. 1999 Nov;21(5):307-12 [10527475.001]
  • [Cites] Ann Endocrinol (Paris). 2008 Jun;69(3):174-80 [18423422.001]
  • [Cites] Am J Clin Pathol. 1996 Dec;106(6):765-8 [8980352.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):135-58 [2578727.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):57-64 [11833496.001]
  • [Cites] Am J Clin Pathol. 1991 Jul;96(1):15-24 [1712540.001]
  • [Cites] Int Surg. 2001 Apr-Jun;86(2):117-21 [11918236.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17 ):4744-9 [8062273.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3494-502 [10550147.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2475-84 [10357421.001]
  • [Cites] Cancer. 1978 Jun;41(6):2267-75 [657091.001]
  • (PMID = 20414675.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / TTF1 protein, human; 68238-35-7 / Keratins
  •  go-up   go-down


80. Takano T, Ito Y, Matsuzuka F, Miya A, Kobayashi K, Yoshida H, Miyauchi A: Expression of oncofetal fibronectin mRNA in thyroid anaplastic carcinoma. Jpn J Clin Oncol; 2007 Sep;37(9):647-51
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of oncofetal fibronectin mRNA in thyroid anaplastic carcinoma.
  • BACKGROUND: Oncofetal fibronectin (onfFN) is a fetal protein, the expression of which is observed in papillary thyroid carcinomas but not in follicular tumors or in normal thyroid.
  • Its expression in anaplastic thyroid carcinoma (ATC), however, has not been clarified, since only a few cases had been examined in previous studies.
  • RESULTS: Increased expression of onfFN mRNA was observed in all cases of ATC regardless of the type of accompanying differentiated carcinoma and five of six ATC cell lines.
  • CONCLUSION: These results confirm that expression of onfFN mRNA characterizes not only papillary thyroid carcinoma but also ATC. onfFN mRNA or protein may be a useful marker to identify anaplastic carcinoma cells and may be considered as an optimistic target in molecular-based therapy of ATC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / chemistry. Fibronectins / analysis. Thyroid Gland / chemistry. Thyroid Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704536.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / RNA, Messenger; 0 / oncofetal fibronectin
  •  go-up   go-down


81. Daneshbod Y, Omidvari S, Daneshbod K, Negahban S, Dehghani M: Diffuse large B cell lymphoma of thyroid as a masquerader of anaplastic carcinoma of thyroid, diagnosed by FNA: a case report. Cytojournal; 2006;3:23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B cell lymphoma of thyroid as a masquerader of anaplastic carcinoma of thyroid, diagnosed by FNA: a case report.
  • BACKGROUND: Both thyroid lymphoma and anaplastic carcinoma of thyroid present with rapidly growing mass in eldery patients.
  • Anaplastic carcinoma has high mortality rate and combination of surgery, radiation therapy and multidrug chemotherapy are the best chance for cure.
  • Fine needle aspiration was done and reported as anaplastic carcinoma of thyroid which thyroidectomy was planned.
  • After review, with initial diagnosis of anaplastic carcinoma versus lymphoma, immunocytochemical study was performed.
  • CONCLUSION: Despite previous reports, stating easy diagnosis of high-grade thyroid lymphoma on the grounds of cytomorphological features we like to emphasize, overlapping cytologic features of the curable high grade thyroid lymphoma form noncurable anaplastic thyroid carcinoma and usefulness of immunocytochemistry to differentiate these two disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1999 Jun;26(3):316-23 [10375088.001]
  • [Cites] Thyroid. 1999 Dec;9(12):1273-80 [10646671.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):623-39 [10800981.001]
  • [Cites] Cytopathology. 2001 Aug;12(4):257-63 [11488875.001]
  • [Cites] Curr Treat Options Oncol. 2004 Aug;5(4):307-13 [15233907.001]
  • [Cites] Cytojournal. 2005;2:21 [16336672.001]
  • [Cites] Diagn Cytopathol. 1991;7(2):163-71 [2065571.001]
  • [Cites] Acta Cytol. 1989 Jan-Feb;33(1):48-52 [2521756.001]
  • [Cites] Diagn Cytopathol. 1987 Sep;3(3):244-9 [3665692.001]
  • [Cites] Diagn Cytopathol. 1993 Dec;9(6):639-45 [8143536.001]
  • [Cites] Am Surg. 1998 Apr;64(4):334-7 [9544144.001]
  • (PMID = 17052355.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1630693
  •  go-up   go-down


82. Takeshita Y, Takamura T, Minato H, Misu H, Ando H, Yamashita T, Ikeda H, Nakanuma Y, Kaneko S: Transformation of p53-positive papillary thyroid carcinoma to anaplastic carcinoma of the liver following postoperative radioactive iodine-131 therapy. Intern Med; 2008;47(19):1709-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of p53-positive papillary thyroid carcinoma to anaplastic carcinoma of the liver following postoperative radioactive iodine-131 therapy.
  • Multiple liver metastases were incidentally detected in the lobe of the liver of an 81-year-old woman following total thyroidectomy and ablative radioactive iodine administration for the treatment of papillary thyroid carcinoma.
  • A biopsy specimen taken from the metastatic liver tumor was histologically diagnosed as anaplastic carcinoma.
  • We considered this to have been caused by anaplastic transformation from papillary thyroid carcinoma during treatment.
  • We report a rare case of multiple liver metastases from a papillary thyroid carcinoma, which we believe to be the result of anaplastic transformation during postoperative radioactive iodine-131 therapy.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Carcinoma, Papillary / radiotherapy. Iodine Radioisotopes / adverse effects. Liver Neoplasms / secondary. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / radiography. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827421.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


83. Namikawa T, Hanazaki K: Clinical analysis of primary anaplastic carcinoma of the small intestine. World J Gastroenterol; 2009 Feb 7;15(5):526-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of primary anaplastic carcinoma of the small intestine.
  • Primary anaplastic carcinoma is a rare variant of small intestinal cancer.
  • Most reports of primary anaplastic carcinoma of the small intestine are isolated case reports, therefore the clinicopathological features, therapeutic management, and surgical outcome of this tumor type remain unclear.
  • This review analyzes the available clinical characteristics of primary anaplastic carcinoma of the small intestine and investigates key differences from differentiated adenocarcinoma of the small intestine.
  • A Medline search was performed using the keywords 'small intestine' and 'anaplastic carcinoma' or 'undifferentiated carcinoma'.
  • The literature revealed a poor prognosis for patients who underwent surgical resection for anaplastic carcinoma of the small intestine, which gave a 3-year overall survival rate of 10.8% and a median survival time of 5.0 mo.
  • The literature suggests that anaplastic carcinoma is markedly more aggressive than differentiated adenocarcinoma of the small intestine.
  • Surgical resection with the aim of complete tumor removal provides the only beneficial therapeutic option for patients with anaplastic carcinoma of the small intestine, because chemotherapy and radiation therapy have no significant effect on the rate of survival.
  • However, despite complete tumor resection, most patients with anaplastic carcinoma of the small intestine are at great risk of disease recurrence.
  • This report also highlights the importance of a systematic diagnostic approach for anaplastic carcinoma of the small intestine.
  • [MeSH-major] Carcinoma / pathology. Intestinal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]
  • [Cites] World J Surg Oncol. 2008;6:12 [18237404.001]
  • [Cites] Surgery. 2000 Oct;128(4):604-12 [11015094.001]
  • [Cites] Gastrointest Endosc. 2001 Feb;53(2):216-20 [11174299.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Lancet. 1973 Jan 6;1(7793):24-6 [4118541.001]
  • [Cites] Ann Surg. 1974 Aug;180(2):157-61 [4842978.001]
  • [Cites] Ann Surg. 1979 Jun;189(6):732-40 [453945.001]
  • [Cites] Am J Surg. 1980 Sep;140(3):396-9 [7425215.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] Am J Surg. 1987 Apr;153(4):350-4 [3565678.001]
  • [Cites] Ann Surg. 1987 Dec;206(6):706-10 [3689007.001]
  • [Cites] Hum Pathol. 1989 Sep;20(9):858-63 [2777242.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1716-23 [8253348.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):300-6 [9060587.001]
  • [Cites] Am J Surg. 1997 Mar;173(3):237-9 [9124635.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):243-51 [9521441.001]
  • [Cites] J Am Coll Surg. 1998 Jun;186(6):664-8 [9632155.001]
  • [Cites] J Clin Gastroenterol. 1999 Jul;29(1):99-101 [10405244.001]
  • [Cites] Cancer Imaging. 2007;7:224-33 [18083648.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • (PMID = 19195053.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2653339
  •  go-up   go-down


84. Kakudo K, Bai Y, Li Y, Wakasa T, Mori I: [Thyroid carcinoma--differentiated, poorly differentiated and anaplastic carcinoma]. Nihon Rinsho; 2007 Nov;65(11):1979-84
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thyroid carcinoma--differentiated, poorly differentiated and anaplastic carcinoma].
  • The poorly differentiated carcinoma was first added as a new member in the lists of classification of thyroid carcinomas in the WHO 2004 edition.
  • This modification creates a significant change in the incidence and prognosis of this carcinoma.
  • This carcinoma, defined by the new WHO classification, is about 1-5% of all thyroid malignancy and has more aggressive outcome than the previous definition.
  • [MeSH-major] Carcinoma / pathology. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018558.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 12
  •  go-up   go-down


85. Ito Y, Higashiyama T, Hirokawa M, Fukushima M, Inoue H, Yabuta T, Tomoda C, Uruno T, Kihara M, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A: Investigation of the validity of UICC stage grouping of anaplastic carcinoma of the thyroid. Asian J Surg; 2009 Jan;32(1):47-50
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of the validity of UICC stage grouping of anaplastic carcinoma of the thyroid.
  • OBJECTIVE: Anaplastic thyroid carcinoma arises from differentiated carcinoma and has a very aggressive character.
  • In this study, we investigated the prognosis of patients with anaplastic carcinoma based on UICC stage.
  • PATIENTS AND METHODS: We investigated the prognosis of 75 patients who were diagnosed as having anaplastic carcinoma at Kuma Hospital between 1983 and 2006.
  • All patients with Stage IVC died of carcinoma within 1 year regardless of whether locally complete resection was performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19321402.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


86. Kuroda N, Iwamura S, Fujishima N, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Lee GH: Anaplastic carcinoma of the pancreas with rhabdoid features and hyaline globule-like structures. Med Mol Morphol; 2007 Sep;40(3):168-71
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma of the pancreas with rhabdoid features and hyaline globule-like structures.
  • Pancreaticoduodenectomy was undertaken, and subsequent histological examination of the tumor disclosed anaplastic carcinoma of the pancreas head.
  • The carcinoma components contained adenocarcinoma and squamous cell carcinoma.
  • Additionally, undifferentiated spindle or pleomorphic cells were seen in continuity with the carcinoma component.
  • Finally, we report here the first case of anaplastic carcinoma of the pancreas with hyaline globule-like structures.
  • [MeSH-major] Carcinoma / pathology. Hyalin / metabolism. Pancreatic Neoplasms / pathology. Rhabdoid Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1106-10 [15452172.001]
  • [Cites] Med Mol Morphol. 2005 Dec;38(4):262-6 [16378236.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):68-79 [11823975.001]
  • [Cites] Int J Surg Pathol. 2004 Apr;12(2):171-7 [15173927.001]
  • [Cites] Ann Diagn Pathol. 2001 Jun;5(3):129-40 [11436166.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1701-10 [10362795.001]
  • [Cites] Ultrastruct Pathol. 2003 Jan-Feb;27(1):7-11 [12554531.001]
  • [Cites] Hum Pathol. 1994 Dec;25(12):1283-9 [7528163.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):642-9 [12717248.001]
  • [Cites] Pathol Int. 2000 Jan;50(1):57-62 [10692179.001]
  • [Cites] Am J Surg Pathol. 1992 Jan;16(1):62-8 [1370193.001]
  • [Cites] World J Gastroenterol. 2005 Feb 14;11(6):926-9 [15682496.001]
  • [Cites] Med Mol Morphol. 2007 Mar;40(1):46-9 [17384990.001]
  • (PMID = 17874050.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Tamiolakis D, Venizelos I, Nikolaidou S, Lambropoulou M, Bolioti S, Papadopoulos N: Ovarian mucinous cystadenocarcinoma with mural nodule of anaplastic carcinoma and synchronous cervical squamous carcinoma. Cesk Patol; 2005 Apr;41(2):66-70
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mucinous cystadenocarcinoma with mural nodule of anaplastic carcinoma and synchronous cervical squamous carcinoma.
  • One especially interesting case involving coincidental cervical carcinoma is presented.
  • The immunohistochemical examination revealed atypical cells in the nodule which were positive for cytokeratin, CEA, and vimentine, establishing its anaplastic nature.
  • A synchronous cervical invasive squamous carcinoma was documented.
  • The occurrence of ovarian mucinous cystadenocarcinoma with mural nodule of anaplastic carcinoma and cervical squamous cell carcinoma is evidently very uncommon, because we have not found a similar case in the literature.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cystadenocarcinoma, Mucinous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966336.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


88. Murata T, Terasaki M, Sakaguchi K, Okubo M, Fukami Y, Nishimae K, Kitayama Y, Hoshi S: A case of anaplastic carcinoma of the pancreas producing granulocyte-colony stimulating factor. Clin J Gastroenterol; 2009 Apr;2(2):109-114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of anaplastic carcinoma of the pancreas producing granulocyte-colony stimulating factor.
  • We report a case of anaplastic carcinoma of the pancreas with production of granulocyte-colony stimulating factor (G-CSF) in a 59-year-old male.
  • Differential diagnosis included pancreatic tumors and submucosal tumor of the stomach, but definite preoperative diagnosis could not be made.
  • Histological examination showed anaplastic carcinoma of the pancreas.
  • Therefore, we diagnosed the tumor as anaplastic carcinoma of the pancreas producing G-CSF.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AMA Arch Pathol. 1954 Aug;58(2):101-11 [13170907.001]
  • [Cites] Cancer. 1951 Sep;4(5):930-5 [14879357.001]
  • [Cites] Hepatogastroenterology. 2006 Nov-Dec;53(72 ):957-9 [17153462.001]
  • [Cites] J Histochem Cytochem. 1990 Feb;38(2):283-6 [1688901.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3438-43 [7542171.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2007 Feb;104(2):233-8 [17283419.001]
  • [Cites] Clin Chem Lab Med. 2007;45(1):30-4 [17243911.001]
  • [Cites] Br J Cancer. 1999 Jan;79(1):40-6 [10408691.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1151-5 [9672350.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):258-9 [11197273.001]
  • [Cites] Surg Today. 2008;38(5):453-7 [18560971.001]
  • [Cites] J Pain Symptom Manage. 2000 Sep;20(3):214-32 [11018340.001]
  • [Cites] Int J Pancreatol. 1996 Apr;19(2):135-9 [8723556.001]
  • [Cites] Jpn J Clin Oncol. 1991 Dec;21(6):395-9 [1666658.001]
  • [Cites] J Clin Gastroenterol. 1998 Dec;27(4):357-60 [9855271.001]
  • [Cites] Gan To Kagaku Ryoho. 2003 Feb;30(2):297-301 [12610883.001]
  • [Cites] Blood. 1977 May;49(5):845-52 [300638.001]
  • (PMID = 26192175.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Anaplastic carcinoma / Granulocyte-colony stimulating factor / Pancreas
  •  go-up   go-down


89. Pan ZG, Wang B: Anaplastic carcinoma of the pancreas associated with a mucinous cystic adenocarcinoma. A case report and review of the literature. JOP; 2007;8(6):775-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma of the pancreas associated with a mucinous cystic adenocarcinoma. A case report and review of the literature.
  • CONTEXT: Anaplastic carcinoma of the pancreas is a rare undifferentiated variant of ductal adenocarcinoma, which commonly displays sarcomatoid spindle-cell and pleomorphic growth patterns.
  • Anaplastic carcinoma of the pancreas associated with mucinous cystic neoplasm has rarely been reported.
  • CASE REPORT: Here we report a unique case of an anaplastic carcinoma of the pancreas in association with a mucinous cystadenocarcinoma in a 70-year-old woman.
  • The anaplastic component of this tumor is predominantly composed of spindle cells and highly pleomorphic cells that mimic a spindle cell sarcoma.
  • Adjacent to the solid anaplastic tumor is a classic mucinous cystadenocarcinoma, which has strong reactivity to mucin 1, CA 19-9, epithelial membrane antigen (EMA), CK19, CK8/18, carcinoembryonic antigen and CK7.
  • The peri-cystic tissue and the septa consist of an ovarian-type stroma that is strongly positive for CD10.
  • CONCLUSION: The anaplastic carcinoma of the pancreas is of epithelial origin with various microscopic features, and the scattered osteoclast-like giant cells in the tumor are reactive cells of histiocytic origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993730.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 15
  •  go-up   go-down


90. Cerilli LA, Frable WJ, Spafford MF: Anaplastic carcinoma of the thyroid with chondroblastoma features mimicking papillary carcinoma: a case report. Acta Cytol; 2007 Sep-Oct;51(5):825-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma of the thyroid with chondroblastoma features mimicking papillary carcinoma: a case report.
  • BACKGROUND: An unusual case of anaplastic carcinoma of the thyroid arising from a metastatic focus of papillary carcinoma.
  • CASE: The tumor affected a 69-year-old woman with a history of total thyroidectomy for papillary thyroid carcinoma 4 years previously.
  • A small, embedded focus of residual follicular variant of papillary carcinoma was present.
  • CONCLUSION: This "chondroblastoma" variant of anaplastic thyroid carcinoma has not been reported to date.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Papillary / pathology. Chondroblastoma / pathology. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Chondroblastoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910356.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


91. Krapp JD, Brauer RB, Matevossian E, Gerauer KE, Thorban S, Becker K, Stangl MJ: Donor transmitted anaplastic carcinoma in a kidney-transplant recipient. Transpl Int; 2005 Sep;18(9):1109-12
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor transmitted anaplastic carcinoma in a kidney-transplant recipient.
  • We report a case in which anaplastic carcinoma tumor cells from an organ-donor were transmitted to a kidney transplantation recipient.
  • [MeSH-major] Carcinoma / etiology. Carcinoma / secondary. Kidney Neoplasms / etiology. Kidney Neoplasms / secondary. Kidney Transplantation / adverse effects. Tissue Donors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101732.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Yamai H, Yoshida T, Toba H, Kira M, Takizawa H, Tangoku A: [A case of anaplastic carcinoma of thyroid administered peroral fluorinated pyrimidine for long-term survival during three years]. Gan To Kagaku Ryoho; 2009 Jun;36(6):1021-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of anaplastic carcinoma of thyroid administered peroral fluorinated pyrimidine for long-term survival during three years].
  • We report a case of anaplastic carcinoma of the thyroid administered peroral fluorinated pyrimidine, providing longterm survival during three years.
  • Three years ago, a 70-year-old woman diagnosed with anaplastic carcinoma of the thyroid was admitted for chemoradiation therapy after tumor resection and tracheostomy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma / drug therapy. Oxonic Acid / administration & dosage. Tegafur / administration & dosage. Thyroid Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542729.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5VT6420TIG / Oxonic Acid; 1-UFT protocol
  •  go-up   go-down


93. Hakamada K, Miura T, Kimura A, Nara M, Toyoki Y, Narumi S, Sasak M: Anaplastic carcinoma associated with a mucinous cystic neoplasm of the pancreas during pregnancy: report of a case and a review of the literature. World J Gastroenterol; 2008 Jan 7;14(1):132-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma associated with a mucinous cystic neoplasm of the pancreas during pregnancy: report of a case and a review of the literature.
  • Oncogenesis of anaplastic carcinoma of the pancreas is a subject of controversy, because it shows sarcomatous nature with extremely poor prognosis.
  • We herein report an unusual case of anaplastic carcinoma occurring with a recurrent mucinous cystic neoplasm in a 38-year-old female.
  • A 10-cm retroperitoneal cystic mass was pointed out in the first pregnancy and a probable diagnosis of mucinous cystic neoplasm was made in October 2000.
  • A diagnosis of borderline-type mucinous cystic neoplasm with ovarian-like stroma was made.
  • Pathology revealed that the tumor was composed of two different components of borderline-type mucinous cystic neoplasm and anaplastic carcinoma.
  • Although the origin of anaplastic carcinoma has not been determined yet, it should be remembered that anaplastic carcinoma can occur in association with mucinous cystic neoplasm of more benign histology.
  • [MeSH-major] Carcinoma / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreatic Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] West J Med. 1982 Feb;136(2):157-62 [6278785.001]
  • [Cites] Cell. 1983 Aug;34(1):245-53 [6192933.001]
  • [Cites] Lab Invest. 1987 Oct;57(4):359-69 [3669613.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):494-8 [1702351.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2792-6 [1333354.001]
  • [Cites] Histopathology. 1995 Mar;26(3):284-7 [7541017.001]
  • [Cites] Am J Clin Pathol. 1978 Jun;69(6):573-80 [665578.001]
  • [Cites] Arch Pathol Lab Med. 1997 May;121(5):533-5 [9167613.001]
  • [Cites] AMA Arch Pathol. 1954 Aug;58(2):101-11 [13170907.001]
  • [Cites] Am J Clin Pathol. 1946 Mar;16:219-24 [21027097.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):86-91 [10658914.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):70-80 [8990143.001]
  • (PMID = 18176976.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 14
  • [Other-IDs] NLM/ PMC2673378
  •  go-up   go-down


94. Besic N, Hocevar M, Zgajnar J, Pogacnik A, Grazio-Frkovic S, Auersperg M: Prognostic factors in anaplastic carcinoma of the thyroid-a multivariate survival analysis of 188 patients. Langenbecks Arch Surg; 2005 Jun;390(3):203-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in anaplastic carcinoma of the thyroid-a multivariate survival analysis of 188 patients.
  • BACKGROUND: Multivariate studies concerning the prognosis of patients with anaplastic carcinoma of the thyroid gland are scarce.
  • The aim of our study was to determine the prognostic factors associated with survival of patients with anaplastic carcinoma in Slovenia, an iodine-deficient region.
  • METHODS: This retrospective study was carried out on a group of 188 patients (130 female, 58 male; median age 68 years) with anaplastic carcinoma of the thyroid who had been treated at a tertiary care centre from 1972 to 2003.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / therapy. Thyroid Neoplasms / mortality. Thyroid Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mayo Clin Proc. 1985 Jan;60(1):51-8 [3965822.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):321-30 [1695118.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1903-11 [2004304.001]
  • [Cites] Eur J Surg Oncol. 1992 Apr;18(2):83-8 [1582515.001]
  • [Cites] Ann Oncol. 2000 Sep;11(9):1083-9 [11061600.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):260-4 [11373102.001]
  • [Cites] Wien Klin Wochenschr. 1990 Apr 27;102(9):267-70 [2375116.001]
  • [Cites] Langenbecks Arch Surg. 1999 Jun;384(3):284-93 [10437618.001]
  • [Cites] World J Surg. 2001 May;25(5):617-22 [11369989.001]
  • [Cites] Surgery. 2002 Mar;131(3):245-8 [11894027.001]
  • [Cites] Thyroid. 1998 Aug;8(8):715-26 [9737368.001]
  • [Cites] Cancer. 1986 Oct 15;58(8):1749-55 [3756796.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):57-64 [11833496.001]
  • [Cites] Surgery. 1995 Dec;118(6):1131-6; discussion 1136-8 [7491533.001]
  • (PMID = 15599758.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


95. Zhou ZY, Sun RC, Yang GY, Yang SD, Yu MH, Liang JB: Giant-cell anaplastic carcinoma with osteoclastic giant cells of the chest cavity: a distinctive form of thymic carcinoma? Int J Surg Pathol; 2010 Oct;18(5):363-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant-cell anaplastic carcinoma with osteoclastic giant cells of the chest cavity: a distinctive form of thymic carcinoma?
  • Here, the authors describe a case of giant-cell anaplastic carcinoma with osteoclastic giant cells of the chest cavity-which could be a distinctive form of thymic carcinoma-which expressed CD5 and CD45.
  • The tumor was composed of large areas of necrosis and anaplastic neoplastic giant cells with high mitotic activity, and osteoclast-like cells; there was marked inflammatory cell infiltration.
  • The anaplastic neoplastic giant cells were immunoreactive for CKpan, CD5, CD45, VIM, and p53.
  • Because this tumor is very rare, extensive clinical, radiological, and morphological examinations as well as immunohistochemical studies are essential to make the diagnosis.
  • [MeSH-major] Carcinoma / pathology. Osteoclasts / pathology. Thoracic Cavity / pathology. Thoracic Neoplasms / pathology. Thymus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20667924.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Biomarkers, Tumor; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


96. Carda C, Ferrer J, Vilanova M, Peydró A, Llombart-Bosch A: Anaplastic carcinoma of the thyroid with rhabdomyosarcomatous differentiation: a report of two cases. Virchows Arch; 2005 Jan;446(1):46-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma of the thyroid with rhabdomyosarcomatous differentiation: a report of two cases.
  • Anaplastic carcinoma of the thyroid gland (ACT) is a highly malignant tumor that is almost invariably associated with a fatal outcome.
  • Both cases disclosed a very similar histological appearance, with a main population of small, pleomorphic, round-to-oval cells arranged in a storiform pattern, admixed with scattered pleomorphic giant cells, an image similar to that of the usual type of MFH.
  • [MeSH-major] Carcinoma / pathology. Rhabdomyosarcoma / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrastruct Pathol. 1984;7(2-3):83-107 [6085434.001]
  • [Cites] Am J Clin Pathol. 1986 Nov;86(5):674-8 [3776922.001]
  • [Cites] Am J Clin Pathol. 1991 Jul;96(1):32-45 [1712542.001]
  • [Cites] Am J Surg Pathol. 1990 Aug;14(8):737-47 [1696070.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):579-87 [9028371.001]
  • [Cites] Acta Pathol Jpn. 1993 Jan-Feb;43(1-2):71-5 [8465659.001]
  • [Cites] Am J Pathol. 1987 Jul;128(1):91-103 [2440309.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1139-45 [11014583.001]
  • [Cites] Pathol Res Pract. 1980 Nov;169(3-4):304-22 [7220381.001]
  • [Cites] Arch Pathol Lab Med. 1987 Dec;111(12):1169-72 [3314789.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1150-7 [11688574.001]
  • [Cites] Cancer. 1975 May;35(5):1280-92 [1122479.001]
  • [Cites] Am J Clin Pathol. 1987 Apr;87(4):434-42 [2435145.001]
  • [Cites] Cancer. 1988 Dec 15;62(12):2558-63 [3056606.001]
  • [Cites] Am J Clin Pathol. 1974 May;61(5):690-6 [4827051.001]
  • [Cites] Semin Diagn Pathol. 1994 Feb;11(1):3-14 [8202645.001]
  • [Cites] Am J Pathol. 1988 Mar;130(3):515-31 [3279794.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):135-58 [2578727.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):595-603 [11406662.001]
  • [Cites] Histopathology. 1987 Jun;11(6):567-80 [2442086.001]
  • [Cites] Hum Pathol. 1990 Dec;21(12):1269-74 [2174404.001]
  • [Cites] Am J Clin Pathol. 1991 Jul;96(1):15-24 [1712540.001]
  • [Cites] Pathology. 1993 Apr;25(2):203-5 [8367205.001]
  • [Cites] Appl Pathol. 1989;7(2):122-33 [2471539.001]
  • [Cites] Semin Diagn Pathol. 1993 May;10(2):159-68 [8367624.001]
  • [Cites] Cancer. 1978 Jun;41(6):2267-75 [657091.001]
  • (PMID = 15517365.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / MyoD Protein; 0 / MyoD1 myogenic differentiation protein; 0 / Myoglobin
  •  go-up   go-down


97. Provenza C, Young RH, Prat J: Anaplastic carcinoma in mucinous ovarian tumors: a clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules. Am J Surg Pathol; 2008 Mar;32(3):383-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma in mucinous ovarian tumors: a clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules.
  • The histopathologic features and prognosis of foci/nodules of anaplastic carcinoma are not well known.
  • Slides from 34 consultation cases of mucinous ovarian tumors with foci/nodules of anaplastic carcinoma were reviewed and classified on the basis of their morphologic features.
  • The foci/nodules of anaplastic carcinoma were classified histologically into 3 groups: (a) rhabdoid (n=12) having a diffuse arrangement of cells with large, bright, eosinophilic cytoplasms, eccentric nuclei, and one or more prominent nucleoli;.
  • The presence of foci/nodules of anaplastic carcinoma in unruptured stage I mucinous tumors of the ovary does not necessarily carry an adverse prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300813.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Vella J, Cracchiolo B, Heller DS: Anaplastic carcinoma arising in an ovarian mucinous cystadenocarcinoma in a 17-year-old female. J Pediatr Adolesc Gynecol; 2006 Feb;19(1):39-43
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma arising in an ovarian mucinous cystadenocarcinoma in a 17-year-old female.
  • BACKGROUND: Anaplastic carcinoma arising within a mucinous ovarian neoplasm is rare, with only about 30 reported cases.
  • CASE: We report a case of anaplastic carcinoma arising in a mucinous cystadenocarcinoma in a 17-year-old female who presented with severe abdominal pain, an unusual symptom for an ovarian malignancy in the postmenopausal patient, but not in the adolescent.
  • CONCLUSIONS: This case illustrates that, although rare, epithelial ovarian malignancy is in the differential diagnosis of abdominal pain in an adolescent.
  • [MeSH-major] Abdominal Pain / etiology. Carcinoma / diagnosis. Cystadenocarcinoma, Mucinous / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Fatal Outcome. Female. Humans

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16472728.001).
  • [ISSN] 1083-3188
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Califano L, Sanguedolce F, Staibano S, Pannone G, Tortorella S, Serpico R, Lo Muzio L, Bufo P: Large oral soft tissue metastasis from anaplastic carcinoma of the lung mimicking a primitive malignancy: case report and brief review of the literature. Minerva Stomatol; 2008 Sep;57(9):447-51
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large oral soft tissue metastasis from anaplastic carcinoma of the lung mimicking a primitive malignancy: case report and brief review of the literature.
  • We describe a case of anaplastic carcinoma of the lung in a 60-year-old man, presenting a huge oral metastasis as the first sign of his primitive lung malignancy.
  • Clinically, the oral lesion mimicked a high-grade primitive carcinoma of the oral cavity.
  • We report an uncommon case of metastatic lung carcinoma to the gingiva emphasizing the differential diagnosis between primary and metastatic tumours; a short discussion on the pathways of metastatization to oral cavity soft tissues, as well as brief review of the literature are also presented.
  • [MeSH-major] Carcinoma / prevention & control. Lung Neoplasms / pathology. Mouth Neoplasms / secondary. Soft Tissue Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18923379.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng; ita
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 8
  •  go-up   go-down


100. Okamoto M, Kitajima S, Negishi R, Maehata T, Kouro T, Yamauchi S, Takahashi H, Katakura Y, Watanabe Y, Abiko R, Nakaya S, Inaba H, Takano T, Suzuki M, Itoh F: [Two cases of anaplastic carcinoma of the pancreas in terms of the diversity of carcinoma cells (epithelial-mesenchymal transition; EMT)]. Nihon Shokakibyo Gakkai Zasshi; 2008 Nov;105(11):1656-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of anaplastic carcinoma of the pancreas in terms of the diversity of carcinoma cells (epithelial-mesenchymal transition; EMT)].
  • A huge tumor mass was observed in the tale of the pancreas, which we diagnosed as pancreatic carcinoma.
  • Pathological findings confirmed that it was anaplastic pancreas carcinoma (giant cell type).
  • Autopsy findings confirmed that it was anaplastic pancreas carcinoma (pleomorphic type).
  • Both cases showed positive for epithelial marker and mesenchymal markers and decrease in stainability by E-cadherin staining, a result which suggested diversity of tumor cells in anaplastic pancreas carcinomas.
  • [MeSH-major] Carcinoma / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987452.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down






Advertisement